{"id":"amoxicillin-and-clavulanate","_fda":{"id":"a2a30785-599c-4436-a3cc-b4db011b7a87","set_id":"00cf4429-e37c-4490-b22d-3cd796124296","openfda":{"unii":["804826J2HU","Q42OMW3AT8"],"route":["ORAL"],"rxcui":["562508"],"spl_id":["a2a30785-599c-4436-a3cc-b4db011b7a87"],"brand_name":["AMOXICILLIN AND CLAVULANATE POTASSIUM"],"spl_set_id":["00cf4429-e37c-4490-b22d-3cd796124296"],"package_ndc":["50090-6324-0","50090-6324-3","50090-6324-1","50090-6324-2"],"product_ndc":["50090-6324"],"generic_name":["AMOXICILLIN AND CLAVULANATE POTASSIUM"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["AMOXICILLIN","CLAVULANATE POTASSIUM"],"manufacturer_name":["A-S Medication Solutions"],"application_number":["NDA050720"],"original_packager_product_ndc":["81964-221"]},"version":"4","pregnancy":["8.1 Pregnancy Teratogenic Effects : Pregnancy Category B. Reproduction studies performed in pregnant rats and mice given Amoxicillin and Clavulanate Potassium (2:1 ratio formulation of amoxicillin:clavulanate) at oral doses up to 1200 mg/kg/day revealed no evidence of harm to the fetus due to Amoxicillin and Clavulanate Potassium. The amoxicillin doses in rats and mice (based on body surface area) were approximately 4 and 2 times the maximum recommended adult human oral dose (875 mg every 12 hours). For clavulanate, these dose multiples were approximately 9 and 4 times the maximum recommended adult human oral dose (125 mg every 8 hours). There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed."],"overdosage":["10 OVERDOSAGE In case of overdosage, discontinue medication, treat symptomatically, and institute supportive measures as required. A prospective study of 51 pediatric patients at a poison-control center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms 1 . Interstitial nephritis resulting in oliguric renal failure has been reported in patients after overdosage with amoxicillin and clavulanate potassium. Crystalluria, in some cases leading to renal failure, has also been reported after amoxicillin and clavulanate potassium overdosage in adult and pediatric patients. In case of overdosage, adequate fluid intake and diuresis should be maintained to reduce the risk of amoxicillin and clavulanate potassium crystalluria. Renal impairment appears to be reversible with cessation of drug administration. High blood levels may occur more readily in patients with impaired renal function because of decreased renal clearance of amoxicillin and clavulanate potassium. Amoxicillin and clavulanate potassium may be removed from circulation by hemodialysis [see Dosage and Administration ( 2.4 )] ."],"references":["15 REFERENCES Swanson-Biearman B, Dean BS, Lopez G, Krenzelok EP. The effects of penicillin and cephalosporin ingestions in children less than six years of age. Vet Hum Toxicol. 1988; 30: 66‑67."],"description":["11 DESCRIPTION Amoxicillin and Clavulanate Potassium is an oral antibacterial combination consisting of amoxicillin and the beta‑lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid). Amoxicillin is an analog of ampicillin, derived from the basic penicillin nucleus, 6‑aminopenicillanic acid. The amoxicillin molecular formula is C 16 H 19 N 3 O 5 S•3H 2 O, and the molecular weight is 419.46. Chemically, amoxicillin is (2 S ,5 R ,6 R )-6-[( R )-(-)-2-Amino-2-( p -hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate and may be represented structurally as: Clavulanic acid is produced by the fermentation of Streptomyces clavuligerus . It is a beta-lactam structurally related to the penicillins and possesses the ability to inactivate some beta‑lactamases by blocking the active sites of these enzymes. The clavulanate potassium molecular formula is C 8 H 8 KNO 5 , and the molecular weight is 237.25. Chemically, clavulanate potassium is potassium ( Z )(2 R ,5 R )-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]-heptane-2-carboxylate and may be represented structurally as: Amoxicillin and Clavulanate Potassium Tablets: 250 mg/125 mg: Each tablet contains 250 mg of amoxicillin as the trihydrate, and 125 mg of clavulanic acid (equivalent to 149 mg of clavulanate potassium). 500 mg/125 mg: Each tablet contains 500 mg of amoxicillin as the trihydrate, and 125 mg of clavulanic acid (equivalent to 149 mg of clavulanate potassium). 875 mg/125 mg: Each tablet contains 875 mg of amoxicillin as the trihydrate, and 125 mg of clavulanic acid (equivalent to 149 mg of clavulanate potassium). Amoxicillin and Clavulanate Potassium for Oral Suspension: 125 mg/31.25 mg : Following constitution, each 5 mL of oral suspension contains 125 mg of amoxicillin as the trihydrate, and 31.25 mg of clavulanic acid (equivalent to 37.23 mg of clavulanate potassium). 200 mg/28.5 mg : Following constitution, each 5 mL of oral suspension contains 200 mg of amoxicillin as the trihydrate, and 28.5 mg of clavulanic acid (equivalent to 34 mg of clavulanate potassium). 250 mg/62.5 mg : Following constitution, each 5 mL of oral suspension contains 250 mg of amoxicillin as the trihydrate, and 62.5 mg of clavulanic acid (equivalent to 74.5 mg of clavulanate potassium). 400 mg/57 mg : Following constitution, each 5 mL of oral suspension contains 400 mg of amoxicillin as the trihydrate, and 57 mg of clavulanic acid (equivalent to 68 mg of clavulanate potassium). Amoxicillin and Clavulanate Potassium Chewable Tablets: 125 mg/31.25 mg: Each chewable tablet contains 125 mg of amoxicillin as the trihydrate, and 31.25 mg of clavulanic acid (equivalent to 37.23 mg of clavulanate potassium). 200 mg/28.5 mg: Each chewable tablet contains 200 mg of amoxicillin as the trihydrate, and 28.5 mg of clavulanic acid (equivalent to 34 mg of clavulanate potassium). 250 mg/62.5 mg: Each chewable tablet contains 250 mg of amoxicillin as the trihydrate, and 62.5 mg of clavulanic acid (equivalent to 74.5 mg of clavulanate potassium). 400 mg/57 mg: Each chewable tablet contains 400 mg of amoxicillin as the trihydrate, and 57 mg of clavulanic acid (equivalent to 68 mg of clavulanate potassium). Inactive Ingredients: Amoxicillin and Clavulanate Potassium Tablets - Colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, and titanium dioxide. • Each tablet of Amoxicillin and Clavulanate Potassium contains 0.63 mEq potassium. Amoxicillin and Clavulanate Potassium for Oral Suspension, 125 mg/31.5 mg per 5mL and 250 mg/62.5 mg per 5mL - Colloidal silicon dioxide, flavorings, xanthan gum, mannitol, succinic acid, silica gel and sodium saccharin. • Each 5 mL of reconstituted 125 mg/31.5 mg oral suspension of Amoxicillin and Clavulanate Potassium contains 0.16 mEq potassium • Each 5 mL of reconstituted 250 mg/62.5 mg oral suspension of Amoxicillin and Clavulanate Potassium contains 0.32 mEq potassium Amoxicillin and Clavulanate Potassium for Oral Suspension, 200 mg/28.5 mg per 5mL and 400 mg/57 mg per 5mL - Colloidal silicon dioxide, flavorings, xanthan gum, silica gel, hypromellose and aspartame [see Warnings and Precautions ( 5.7 )] • Each 5 mL of reconstituted 200 mg/28.5 mg oral suspension of Amoxicillin and Clavulanate Potassium contains 0.14 mEq potassium • Each 5 mL of reconstituted 400 mg/57 mg oral suspension of Amoxicillin and Clavulanate Potassium contains 0.29 mEq potassium Amoxicillin and Clavulanate Potassium Chewable Tablets, 125 mg/31.25 mg and 250 mg/62.5 mg - Colloidal silicon dioxide, flavorings, magnesium stearate, mannitol, sodium saccharin, glycine, and D&C Yellow No.10. Each 125 mg/31.25 mg chewable tablet of Amoxicillin and Clavulanate Potassium contains 0.16 mEq potassium Each 250 mg/62.5 mg chewable tablet of Amoxicillin and Clavulanate Potassium contains 0.32 mEq potassium Amoxicillin and Clavulanate Potassium Chewable Tablets, 200 mg/28.5 mg and 400 mg/57 mg - Colloidal silicon dioxide, flavorings, magnesium stearate, mannitol, FD&C Red No. 40 and aspartame [see Warnings and Precautions ( 5.7 )] Each 200 mg/28.5 mg chewable tablet of Amoxicillin and Clavulanate Potassium contains 0.14 mEq potassium Each 400 mg/57 mg chewable tablet of Amoxicillin and Clavulanate Potassium contains 0.29 mEq potassium structure-amoxicillin structure-clav-acid"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Product: 50090-6324 NDC: 50090-6324-0 20 TABLET, COATED in a BOTTLE NDC: 50090-6324-1 10 TABLET, COATED in a BOTTLE NDC: 50090-6324-2 14 TABLET, COATED in a BOTTLE NDC: 50090-6324-3 28 TABLET, COATED in a BOTTLE"],"microbiology":["12.4 Microbiology Amoxicillin is a semisynthetic antibacterial with in vitro bactericidal activity against Gram-positive and Gram-negative bacteria. Amoxicillin is, however, susceptible to degradation by beta-lactamases, and therefore, the spectrum of activity does not include organisms which produce these enzymes. Clavulanic acid is a beta-lactam, structurally related to the penicillins, which possesses the ability to inactivate some beta-lactamase enzymes commonly found in microorganisms resistant to penicillins and cephalosporins. In particular, it has good activity against the clinically important plasmid-mediated beta-lactamases frequently responsible for transferred drug resistance. The formulation of amoxicillin and clavulanic acid in Amoxicillin and Clavulanate Potassium protects amoxicillin from degradation by some beta-lactamase enzymes and extends the antibacterial spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin. Amoxicillin and clavulanic acid has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infections [see Indications and Usage ( 1 )] . Gram-positive bacteria Staphylococcus aureus Gram-negative bacteria Enterobacter species Escherichia coli Haemophilus influenzae Klebsiella species Moraxella catarrhalis The following in vitro data are available, but their clinical significance is unknown . At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for amoxicillin and clavulanic acid. However, the efficacy of amoxicillin and clavulanic acid in treating clinical infections due to these bacteria has not been established in adequate and well-controlled clinical trials. Gram-positive bacteria Enterococcus faecalis Staphylococcus epidermidis Staphylococcus saprophyticus Streptococcus pneumoniae Streptococcus pyogenes Viridans group Streptococcus Gram-negative Bacteria Eikenella corrodens Proteus mirabilis Anaerobic Bacteria Bacteroides species including Bacteroides fragilis Fusobacterium species Peptostreptococcus species Susceptibility Test Methods For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC ."],"geriatric_use":["8.5 Geriatric Use Of the 3,119 patients in an analysis of clinical studies of Amoxicillin and Clavulanate Potassium, 32% were greater than or equal to 65 years old, and 14% were greater than or equal to 75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets have been established in pediatric patients. Use of Amoxicillin and Clavulanate Potassium in pediatric patients is supported by evidence from studies of Amoxicillin and Clavulanate Potassium Tablets in adults with additional data from a study of Amoxicillin and Clavulanate Potassium for Oral Suspension in pediatric patients aged 2 months to 12 years with acute otitis media [see Clinical Studies ( 14.2 )] . Because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed; clavulanate elimination is unaltered in this age group. Dosing of Amoxicillin and Clavulanate Potassium should be modified in pediatric patients aged less than 12 weeks (less than 3 months) [see Dosage and Administration ( 2.3 )]."],"effective_time":"20240430","nursing_mothers":["8.3 Nursing Mothers Amoxicillin has been shown to be excreted in human milk. Amoxicillin and clavulanate potassium use by nursing mothers may lead to sensitization of infants. Caution should be exercised when amoxicillin and clavulanate potassium is administered to a nursing woman."],"clinical_studies":["14 CLINICAL STUDIES 14.1 Lower Respiratory Tract and Complicated Urinary Tract Infections Data from 2 pivotal trials in 1,191 patients treated for either lower respiratory tract infections or complicated urinary tract infections compared a regimen of 875 mg/125 mg tablets of Amoxicillin and Clavulanate Potassium every 12 hours to 500 mg/125 mg tablets of Amoxicillin and Clavulanate Potassium dosed every 8 hours (584 and 607 patients, respectively). Comparable efficacy was demonstrated between the every 12 hours and every 8 hours dosing regimens. There was no significant difference in the percentage of adverse events in each group. The most frequently reported adverse event was diarrhea; incidence rates were similar for the 875 mg/125 mg every 12 hours and 500 mg/125 mg every 8 hours dosing regimens (15% and 14%, respectively); however, there was a statistically significant difference (p less than 0.05) in rates of severe diarrhea or withdrawals with diarrhea between the regimens: 1% for 875 mg/125 mg every 12 hours regimen versus 2% for the 500 mg/125 mg every 8 hours regimen. In one of these pivotal trials, patients with either pyelonephritis (n equals 361) or a complicated urinary tract infection (i.e., patients with abnormalities of the urinary tract that predispose to relapse of bacteriuria following eradication, n equals 268) were randomized (1:1) to receive either 875 mg/125mg tablets of Amoxicillin and Clavulanate Potassium every 12 hours (n equals 308) or 500 mg/125 mg tablets of Amoxicillin and Clavulanate Potassium every 8 hours (n equals 321). The number of bacteriologically evaluable patients was comparable between the two dosing regimens. Amoxicillin and Clavulanate Potassium produced comparable bacteriological success rates in patients assessed 2 to 4 days immediately following end of therapy. The bacteriologic efficacy rates were comparable at one of the follow‑up visits (5 to 9 days post‑therapy) and at a late post‑therapy visit (in the majority of cases, this was 2 to 4 weeks post-therapy), as seen in Table 8. Table 8: Bacteriologic efficacy rates for Amoxicillin and Clavulanate Potassium Time Post Therapy 875 mg every 12 hours % (n) 500 mg every 8 hours % (n) 2 to 4 days 81% (58) 80% (54) 5 to 9 days 58% (41) 52% (52) 2 to 4 weeks 52% (101) 55% (104) As noted before, though there was no significant difference in the percentage of adverse events in each group, there was a statistically significant difference in rates of severe diarrhea or withdrawals with diarrhea between the regimens. 14.2 Acute Bacterial Otitis Media and Diarrhea in Pediatric Patients One US/Canadian clinical trial was conducted which compared 45/6.4 mg/kg/day (divided every 12 hours) of Amoxicillin and Clavulanate Potassium for 10 days versus 40/10 mg/kg/day (divided every 8 hours) of Amoxicillin and Clavulanate Potassium for 10 days in the treatment of acute otitis media. Only the suspension formulations were used in this trial. A total of 575 pediatric patients (aged 2 months to 12 years) were enrolled, with an even distribution among the 2 treatment groups and a comparable number of patients were evaluable (i.e., greater than or equal to 84%) per treatment group. Otitis media‑specific criteria were required for eligibility and a strong correlation was found at the end of therapy and follow‑up between these criteria and physician assessment of clinical response. The clinical efficacy rates at the end of therapy visit (defined as 2 to 4 days after the completion of therapy) and at the follow‑up visit (defined as 22 to 28 days post‑completion of therapy) were comparable for the 2 treatment groups, with the following cure rates obtained for the evaluable patients: At end of therapy, 87% (n equals 265) and 82% (n equals 260) for 45 mg/kg/day every 12 hours and 40 mg/kg/day every 8 hours, respectively. At follow‑up, 67% (n equals 249) and 69% (n equals 243) for 45 mg/kg/day every 12 hours and 40 mg/kg/day every 8 hours, respectively. Diarrhea was defined as either: (a) 3 or more watery or 4 or more loose/watery stools in 1 day; OR (b) 2 watery stools per day or 3 loose/watery stools per day for 2 consecutive days. The incidence of diarrhea was significantly lower in patients who received the every 12 hours regimen compared to patients who received the every 8 hours regimen (14% and 34%, respectively). In addition, the number of patients with either severe diarrhea or who were withdrawn with diarrhea was significantly lower in the every 12 hours treatment group (3% and 8% for the every 12 hours/10 day and every 8 hours/10 day, respectively). In the every 12 hours treatment group, 3 patients (1%) were withdrawn with an allergic reaction, while 1 patient in the every 8 hours group was withdrawn for this reason. The number of patients with a candidal infection of the diaper area was 4% and 6% for the every 12 hours and every 8 hours groups, respectively. It is not known if the finding of a statistically significant reduction in diarrhea with the oral suspensions dosed every 12 hours, versus suspensions dosed every 8 hours of Amoxicillin and Clavulanate Potassium, can be extrapolated to the chewable tablets. The presence of mannitol in the chewable tablets of Amoxicillin and Clavulanate Potassium may contribute to a different diarrhea profile. The every 12 hour oral suspensions (200 mg/28.5 mg per 5 mL and 400 mg/57 mg per 5 mL) are sweetened with aspartame."],"laboratory_tests":["7.5 Effects on Laboratory Tests High urine concentrations of amoxicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST ® , Benedict's Solution, or Fehling's Solution. Since this effect may also occur with Amoxicillin and Clavulanate Potassium, it is recommended that glucose tests based on enzymatic glucose oxidase reactions be used. Following administration of amoxicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted."],"pharmacokinetics":["12.3 Pharmacokinetics Mean amoxicillin and clavulanate potassium pharmacokinetic parameters in normal adults following administration of Amoxicillin and Clavulanate Potassium Tablets are shown in Table 6 and following administration of Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets are shown in Table 7. Table 6: Mean (±S.D.) Amoxicillin and Clavulanate Potassium Pharmacokinetic Parameters a,b with Amoxicillin and Clavulanate Potassium Tablets a Mean (± standard deviation) values of 14 normal adults (N equals15 for clavulanate potassium in the low-dose regimens). Peak concentrations occurred approximately 1.5 hours after the dose. b Amoxicillin and clavulanate potassium administered at the start of a light meal. Dose and Regimen of Amoxicillin and Clavulanate C max (mcg/mL) AUC 0-24 (mcg*h/mL) Amoxicillin and Clavulanate potassium Amoxicillin Clavulanate potassium Amoxicillin Clavulanate potassium 250 mg/125 mg every 8 hours 3.3 ± 1.12 1.5 ± 0.70 26.7 ± 4.56 12.6 ± 3.25 500 mg/125 mg every 12 hours 6.5 ± 1.41 1.8 ± 0.61 33.4 ± 6.76 8.6 ± 1.95 500 mg/125 mg every 8 hours 7.2 ± 2.26 2.4 ± 0.83 53.4 ± 8.87 15.7 ± 3.86 875 mg/125 mg every 12 hours 11.6 ± 2.78 2.2 ± 0.99 53.5 ± 12.31 10.2 ± 3.04 Table 7: Mean (±S.D.) Amoxicillin and Clavulanate Potassium Pharmacokinetic Parameters a,b with Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets a Mean (± standard deviation) values of 28 normal adults. Peak concentrations occurred approximately 1 hour after the dose. b Amoxicillin and clavulanate potassium administered at the start of a light meal. Dose of Amoxicillin and Clavulanate C max (mcg/mL) AUC 0-24 (mcg*h/mL) Amoxicillin and Clavulanate potassium Amoxicillin Clavulanate potassium Amoxicillin Clavulanate potassium 400 mg/57 mg (5 mL of suspension) 6.94 ± 1.24 1.10 ± 0.42 17.29 ± 2.28 2.34 ± 0.94 400 mg/57 mg (1 chewable tablet) 6.67 ± 1.37 1.03 ± 0.33 17.24 ± 2.64 2.17 ± 0.73 Oral administration of 5 mL of the 250 mg/62.5 mg suspension of Amoxicillin and Clavulanate Potassium or the equivalent dose of 10 mL of the 125 mg/31.25 mg suspension of Amoxicillin and Clavulanate Potassium provides average peak serum concentrations approximately 1 hour after dosing of 6.9 mcg/mL for amoxicillin and 1.6 mcg/mL for clavulanic acid. The areas under the serum concentration curves obtained during the first 4 hours after dosing were 12.6 mcg*h/mL for amoxicillin and 2.9 mcg*h/mL for clavulanic acid when 5 mL of the 250 mg/62.5 mg suspension of Amoxicillin and Clavulanate Potassium or equivalent dose of 10 mL of the 125 mg/31.25 mg suspension of Amoxicillin and Clavulanate Potassium were administered to normal adults. One 250 mg/62.5 mg chewable tablet of Amoxicillin and Clavulanate Potassium or two 125 mg/31.25 mg chewable tablets of Amoxicillin and Clavulanate Potassium are equivalent to 5 mL of the 250 mg/62.5 mg suspension of Amoxicillin and Clavulanate Potassium and provide similar serum concentrations of amoxicillin and clavulanic acid. Amoxicillin serum concentrations achieved with Amoxicillin and Clavulanate Potassium are similar to those produced by the oral administration of equivalent doses of amoxicillin alone. Time above the minimum inhibitory concentration of 1 mcg/mL for amoxicillin has been shown to be similar after corresponding every 12 hour and every 8-hour dosing regimens of Amoxicillin and Clavulanate Potassium in adults and children. Absorption : Dosing in the fasted or fed state has minimal effect on the pharmacokinetics of amoxicillin. While Amoxicillin and Clavulanate Potassium can be given without regard to meals, absorption of clavulanate potassium when taken with food is greater relative to the fasted state. In one study, the relative bioavailability of clavulanate was reduced when Amoxicillin and Clavulanate Potassium was dosed at 30 and 150 minutes after the start of a high‑fat breakfast. Distribution : Neither component in Amoxicillin and Clavulanate Potassium is highly protein‑bound; clavulanic acid is approximately 25% bound to human serum and amoxicillin approximately 18% bound. Amoxicillin diffuses readily into most body tissues and fluids with the exception of the brain and spinal fluid. Two hours after oral administration of a single 35 mg/kg dose of suspension of Amoxicillin and Clavulanate Potassium to fasting children, average concentrations of 3 mcg/mL of amoxicillin and 0.5 mcg/mL of clavulanic acid were detected in middle ear effusions. Metabolism and Excretion: The half‑life of amoxicillin after the oral administration of Amoxicillin and Clavulanate Potassium is 1.3 hours and that of clavulanic acid is 1 hour. Approximately 50% to 70% of the amoxicillin and approximately 25% to 40% of the clavulanic acid are excreted unchanged in urine during the first 6 hours after administration of a single 250 mg/125 mg or 500 mg/125 mg tablet of Amoxicillin and Clavulanate Potassium."],"adverse_reactions":["6 ADVERSE REACTIONS The following are discussed in more detail in other sections of the labeling: Anaphylactic reactions [see Warnings and Precautions (5.1) ] Severe Cutaneous Adverse Reactions [see Warnings and Precautions ( 5.2 )] Hepatic Dysfunction [see Warnings and Precautions (5.3) ] Clostridioides difficile Associated Diarrhea (CDAD) [see Warnings and Precautions (5.4) ] The most frequently reported adverse effects were diarrhea/loose stools (9%), nausea (3%), skin rashes and urticaria (3%), vomiting (1%) and vaginitis (1%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact USAntibiotics, LLC at 1-844-454-5532 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most frequently reported adverse reactions were diarrhea/loose stools (9%), nausea (3%), skin rashes and urticaria (3%), vomiting (1%) and vaginitis (1%). Less than 3% of patients discontinued therapy because of drug‑related adverse reactions. The overall incidence of adverse reactions, and in particular diarrhea, increased with the higher recommended dose. Other less frequently reported adverse reactions (less than 1%) include: Abdominal discomfort, flatulence, and headache. In pediatric patients (aged 2 months to 12 years), 1 US/Canadian clinical trial was conducted which compared 45/6.4 mg/kg/day (divided every 12 hours) of Amoxicillin and Clavulanate Potassium for 10 days versus 40/10 mg/kg/day (divided every 8 hours) of Amoxicillin and Clavulanate Potassium for 10 days in the treatment of acute otitis media. A total of 575 patients were enrolled, and only the suspension formulations were used in this trial. Overall, the adverse reactions seen were comparable to that noted above; however, there were differences in the rates of diarrhea, skin rashes/urticaria, and diaper area rashes. [see Clinical Studies ( 14.2 )] . 6.2 Postmarketing Experience In addition to adverse reactions reported from clinical trials, the following have been identified during postmarketing use of Amoxicillin and Clavulanate Potassium. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to Amoxicillin and Clavulanate Potassium. Gastrointestinal: Indigestion, gastritis, stomatitis, glossitis, black “hairy” tongue, mucocutaneous candidiasis, enterocolitis, and hemorrhagic/pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment. [see Warnings and Precautions ( 5.4 )] . Immune: Hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock), angioedema, serum sickness-like reactions (urticaria or skin rash accompanied by arthritis, arthralgia, myalgia, and frequently fever), hypersensitivity vasculitis [see Warnings and Precautions ( 5.1 )] . Skin and Appendages: Rashes, pruritus, urticaria, erythema multiforme, SJS, TEN, DRESS, AGEP, exfoliative dermatitis [see Warnings and Precautions ( 5.2 )] . Liver: Hepatic dysfunction, including hepatitis and cholestatic jaundice, increases in serum transaminases (AST and/or ALT), serum bilirubin, and/or alkaline phosphatase, has been reported with Amoxicillin and Clavulanate Potassium. It has been reported more commonly in the elderly, in males, or in patients on prolonged treatment. The histologic findings on liver biopsy have consisted of predominantly cholestatic, hepatocellular, or mixed cholestatic hepatocellular changes. The onset of signs/symptoms of hepatic dysfunction may occur during or several weeks after therapy has been discontinued. The hepatic dysfunction, which may be severe, is usually reversible. Deaths have been reported [see Contraindications ( 4.2 ), Warnings and Precautions ( 5.3 )] . Renal: Interstitial nephritis, hematuria, and crystalluria have been reported [see Overdosage ( 10 )] . Hemic and Lymphatic Systems: Anemia, including hemolytic anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, and agranulocytosis have been reported. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena. Thrombocytosis was noted in less than 1% of the patients treated with Amoxicillin and Clavulanate Potassium. There have been reports of increased prothrombin time in patients receiving Amoxicillin and Clavulanate Potassium and anticoagulant therapy concomitantly [see Drug Interactions ( 7.2 )] . Central Nervous System: Agitation, anxiety, behavioral changes, aseptic meningitis, confusion, convulsions, dizziness, insomnia, and reversible hyperactivity have been reported. Miscellaneous: Tooth discoloration (brown, yellow, or gray staining) has been reported. Most reports occurred in pediatric patients. Discoloration was reduced or eliminated with brushing or dental cleaning in most cases."],"contraindications":["4 CONTRAINDICATIONS History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to Amoxicillin and Clavulanate Potassium or to other beta‑lactams (e.g., penicillins or cephalosporins). ( 4.1 ) History of cholestatic jaundice/hepatic dysfunction associated with Amoxicillin and Clavulanate Potassium. ( 4.2 ) 4.1 Serious Hypersensitivity Reactions Amoxicillin and Clavulanate Potassium is contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin, clavulanate or to other beta‑lactam antibacterial drugs (e.g., penicillins and cephalosporins). 4.2 Cholestatic Jaundice/Hepatic Dysfunction Amoxicillin and Clavulanate Potassium is contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with Amoxicillin and Clavulanate Potassium."],"drug_interactions":["7 DRUG INTERACTIONS Co‑administration with probenecid is not recommended. ( 7.1 ) Concomitant use of Amoxicillin and Clavulanate Potassium and oral anticoagulants may increase the prolongation of prothrombin time.( 7.2 ) Co-administration with allopurinol increases the risk of rash. ( 7.3 ) Amoxicillin and Clavulanate Potassium may reduce efficacy of oral contraceptives. ( 7.4 ) 7.1 Probenecid Probenecid decreases the renal tubular secretion of amoxicillin but does not delay renal excretion of clavulanic acid. Concurrent use with Amoxicillin and Clavulanate Potassium may result in increased and prolonged blood concentrations of amoxicillin. Co-administration of probenecid is not recommended. 7.2 Oral Anticoagulants Abnormal prolongation of prothrombin time (increased international normalized ratio [INR]) has been reported in patients receiving amoxicillin and oral anticoagulants. Appropriate monitoring should be undertaken when anticoagulants are prescribed concurrently with Amoxicillin and Clavulanate Potassium. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation. 7.3 Allopurinol The concurrent administration of allopurinol and amoxicillin increases the incidence of rashes in patients receiving both drugs as compared to patients receiving amoxicillin alone. It is not known whether this potentiation of amoxicillin rashes is due to allopurinol or the hyperuricemia present in these patients. 7.4 Oral Contraceptives Amoxicillin and Clavulanate Potassium may affect intestinal flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives. 7.5 Effects on Laboratory Tests High urine concentrations of amoxicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST ® , Benedict's Solution, or Fehling's Solution. Since this effect may also occur with Amoxicillin and Clavulanate Potassium, it is recommended that glucose tests based on enzymatic glucose oxidase reactions be used. Following administration of amoxicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted."],"labor_and_delivery":["8.2 Labor and Delivery Oral ampicillin‑class antibacterials are poorly absorbed during labor. It is not known whether use of amoxicillin and clavulanate potassium in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood of the necessity for an obstetrical intervention."],"mechanism_of_action":["12.1 Mechanism of Action Amoxicillin and Clavulanate Potassium is an antibacterial drug [see Microbiology ( 12.4 )] ."],"teratogenic_effects":["Teratogenic Effects : Pregnancy Category B. Reproduction studies performed in pregnant rats and mice given Amoxicillin and Clavulanate Potassium (2:1 ratio formulation of amoxicillin:clavulanate) at oral doses up to 1200 mg/kg/day revealed no evidence of harm to the fetus due to Amoxicillin and Clavulanate Potassium. The amoxicillin doses in rats and mice (based on body surface area) were approximately 4 and 2 times the maximum recommended adult human oral dose (875 mg every 12 hours). For clavulanate, these dose multiples were approximately 9 and 4 times the maximum recommended adult human oral dose (125 mg every 8 hours). There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed."],"recent_major_changes":["Warnings and Precautions ( 5 ) 8/2022"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Amoxicillin and Clavulanate Potassium is an antibacterial drug [see Microbiology ( 12.4 )] . 12.3 Pharmacokinetics Mean amoxicillin and clavulanate potassium pharmacokinetic parameters in normal adults following administration of Amoxicillin and Clavulanate Potassium Tablets are shown in Table 6 and following administration of Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets are shown in Table 7. Table 6: Mean (±S.D.) Amoxicillin and Clavulanate Potassium Pharmacokinetic Parameters a,b with Amoxicillin and Clavulanate Potassium Tablets a Mean (± standard deviation) values of 14 normal adults (N equals15 for clavulanate potassium in the low-dose regimens). Peak concentrations occurred approximately 1.5 hours after the dose. b Amoxicillin and clavulanate potassium administered at the start of a light meal. Dose and Regimen of Amoxicillin and Clavulanate C max (mcg/mL) AUC 0-24 (mcg*h/mL) Amoxicillin and Clavulanate potassium Amoxicillin Clavulanate potassium Amoxicillin Clavulanate potassium 250 mg/125 mg every 8 hours 3.3 ± 1.12 1.5 ± 0.70 26.7 ± 4.56 12.6 ± 3.25 500 mg/125 mg every 12 hours 6.5 ± 1.41 1.8 ± 0.61 33.4 ± 6.76 8.6 ± 1.95 500 mg/125 mg every 8 hours 7.2 ± 2.26 2.4 ± 0.83 53.4 ± 8.87 15.7 ± 3.86 875 mg/125 mg every 12 hours 11.6 ± 2.78 2.2 ± 0.99 53.5 ± 12.31 10.2 ± 3.04 Table 7: Mean (±S.D.) Amoxicillin and Clavulanate Potassium Pharmacokinetic Parameters a,b with Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets a Mean (± standard deviation) values of 28 normal adults. Peak concentrations occurred approximately 1 hour after the dose. b Amoxicillin and clavulanate potassium administered at the start of a light meal. Dose of Amoxicillin and Clavulanate C max (mcg/mL) AUC 0-24 (mcg*h/mL) Amoxicillin and Clavulanate potassium Amoxicillin Clavulanate potassium Amoxicillin Clavulanate potassium 400 mg/57 mg (5 mL of suspension) 6.94 ± 1.24 1.10 ± 0.42 17.29 ± 2.28 2.34 ± 0.94 400 mg/57 mg (1 chewable tablet) 6.67 ± 1.37 1.03 ± 0.33 17.24 ± 2.64 2.17 ± 0.73 Oral administration of 5 mL of the 250 mg/62.5 mg suspension of Amoxicillin and Clavulanate Potassium or the equivalent dose of 10 mL of the 125 mg/31.25 mg suspension of Amoxicillin and Clavulanate Potassium provides average peak serum concentrations approximately 1 hour after dosing of 6.9 mcg/mL for amoxicillin and 1.6 mcg/mL for clavulanic acid. The areas under the serum concentration curves obtained during the first 4 hours after dosing were 12.6 mcg*h/mL for amoxicillin and 2.9 mcg*h/mL for clavulanic acid when 5 mL of the 250 mg/62.5 mg suspension of Amoxicillin and Clavulanate Potassium or equivalent dose of 10 mL of the 125 mg/31.25 mg suspension of Amoxicillin and Clavulanate Potassium were administered to normal adults. One 250 mg/62.5 mg chewable tablet of Amoxicillin and Clavulanate Potassium or two 125 mg/31.25 mg chewable tablets of Amoxicillin and Clavulanate Potassium are equivalent to 5 mL of the 250 mg/62.5 mg suspension of Amoxicillin and Clavulanate Potassium and provide similar serum concentrations of amoxicillin and clavulanic acid. Amoxicillin serum concentrations achieved with Amoxicillin and Clavulanate Potassium are similar to those produced by the oral administration of equivalent doses of amoxicillin alone. Time above the minimum inhibitory concentration of 1 mcg/mL for amoxicillin has been shown to be similar after corresponding every 12 hour and every 8-hour dosing regimens of Amoxicillin and Clavulanate Potassium in adults and children. Absorption : Dosing in the fasted or fed state has minimal effect on the pharmacokinetics of amoxicillin. While Amoxicillin and Clavulanate Potassium can be given without regard to meals, absorption of clavulanate potassium when taken with food is greater relative to the fasted state. In one study, the relative bioavailability of clavulanate was reduced when Amoxicillin and Clavulanate Potassium was dosed at 30 and 150 minutes after the start of a high‑fat breakfast. Distribution : Neither component in Amoxicillin and Clavulanate Potassium is highly protein‑bound; clavulanic acid is approximately 25% bound to human serum and amoxicillin approximately 18% bound. Amoxicillin diffuses readily into most body tissues and fluids with the exception of the brain and spinal fluid. Two hours after oral administration of a single 35 mg/kg dose of suspension of Amoxicillin and Clavulanate Potassium to fasting children, average concentrations of 3 mcg/mL of amoxicillin and 0.5 mcg/mL of clavulanic acid were detected in middle ear effusions. Metabolism and Excretion: The half‑life of amoxicillin after the oral administration of Amoxicillin and Clavulanate Potassium is 1.3 hours and that of clavulanic acid is 1 hour. Approximately 50% to 70% of the amoxicillin and approximately 25% to 40% of the clavulanic acid are excreted unchanged in urine during the first 6 hours after administration of a single 250 mg/125 mg or 500 mg/125 mg tablet of Amoxicillin and Clavulanate Potassium. 12.4 Microbiology Amoxicillin is a semisynthetic antibacterial with in vitro bactericidal activity against Gram-positive and Gram-negative bacteria. Amoxicillin is, however, susceptible to degradation by beta-lactamases, and therefore, the spectrum of activity does not include organisms which produce these enzymes. Clavulanic acid is a beta-lactam, structurally related to the penicillins, which possesses the ability to inactivate some beta-lactamase enzymes commonly found in microorganisms resistant to penicillins and cephalosporins. In particular, it has good activity against the clinically important plasmid-mediated beta-lactamases frequently responsible for transferred drug resistance. The formulation of amoxicillin and clavulanic acid in Amoxicillin and Clavulanate Potassium protects amoxicillin from degradation by some beta-lactamase enzymes and extends the antibacterial spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin. Amoxicillin and clavulanic acid has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infections [see Indications and Usage ( 1 )] . Gram-positive bacteria Staphylococcus aureus Gram-negative bacteria Enterobacter species Escherichia coli Haemophilus influenzae Klebsiella species Moraxella catarrhalis The following in vitro data are available, but their clinical significance is unknown . At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for amoxicillin and clavulanic acid. However, the efficacy of amoxicillin and clavulanic acid in treating clinical infections due to these bacteria has not been established in adequate and well-controlled clinical trials. Gram-positive bacteria Enterococcus faecalis Staphylococcus epidermidis Staphylococcus saprophyticus Streptococcus pneumoniae Streptococcus pyogenes Viridans group Streptococcus Gram-negative Bacteria Eikenella corrodens Proteus mirabilis Anaerobic Bacteria Bacteroides species including Bacteroides fragilis Fusobacterium species Peptostreptococcus species Susceptibility Test Methods For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC ."],"indications_and_usage":["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species. Amoxicillin and Clavulanate Potassium is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta‑lactamase inhibitor indicated for treatment of the following infections in adults and pediatric patients: ( 1 ) Lower respiratory tract infections Acute bacterial otitis media Sinusitis Skin and skin structure infections Urinary tract infections Limitations of Use When susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, Amoxicillin and Clavulanate Potassium should not be used. ( 1 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Amoxicillin and Clavulanate Potassium and other antibacterial drugs, Amoxicillin and Clavulanate Potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1 ) Limitations of Use When susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, Amoxicillin and Clavulanate Potassium should not be used. Usage To reduce the development of drug‑resistant bacteria and maintain the effectiveness of Amoxicillin and Clavulanate Potassium and other antibacterial drugs, Amoxicillin and Clavulanate Potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Serious (including fatal) hypersensitivity reactions: Discontinue Amoxicillin and Clavulanate Potassium if a reaction occurs. ( 5.1 ) Severe Cutaneous Adverse Reactions (SCAR): Monitor closely. Discontinue if rash progresses. ( 5.2 ) Hepatic dysfunction and cholestatic jaundice: Discontinue if signs/symptoms of hepatitis occur. Monitor liver function tests in patients with hepatic impairment. ( 5.3 ) Clostridioides difficile -associated diarrhea (CDAD): Evaluate patients if diarrhea occurs. ( 5.4 ) Patients with mononucleosis who receive Amoxicillin and Clavulanate Potassium develop skin rash. Avoid Amoxicillin and Clavulanate Potassium use in these patients. ( 5.5 ) Overgrowth: The possibility of superinfections with fungal or bacterial pathogens should be considered during therapy. ( 5.6 ) 5.1 Hypersensitivity Reactions Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterials, including Amoxicillin and Clavulanate Potassium. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens. Before initiating therapy with Amoxicillin and Clavulanate Potassium, careful inquiry should be made regarding previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens. If an allergic reaction occurs, Amoxicillin and Clavulanate Potassium should be discontinued, and appropriate therapy instituted. 5.2 Severe Cutaneous Adverse Reactions Amoxicillin and Clavulanate Potassium may cause severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). If patients develop a skin rash, they should be monitored closely, and Amoxicillin and Clavulanate Potassium discontinued if lesions progress. 5.3 Hepatic Dysfunction Hepatic dysfunction, including hepatitis and cholestatic jaundice has been associated with the use of Amoxicillin and Clavulanate Potassium. Hepatic toxicity is usually reversible; however, deaths have been reported. Hepatic function should be monitored at regular intervals in patients with hepatic impairment. 5.4 Clostridioides difficile Associated Diarrhea (CDAD) Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Amoxicillin and Clavulanate Potassium, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated. 5.5 Skin Rash in Patients with Mononucleosis A high percentage of patients with mononucleosis who receive amoxicillin develop an erythematous skin rash. Thus, Amoxicillin and Clavulanate Potassium should not be administered to patients with mononucleosis. 5.6 Potential for Microbial Overgrowth The possibility of superinfections with fungal or bacterial pathogens should be considered during therapy. If superinfection occurs, amoxicillin and clavulanate potassium should be discontinued and appropriate therapy instituted. 5.7 Phenylketonurics Amoxicillin and Clavulanate Potassium Chewable tablets and Amoxicillin and Clavulanate Potassium for Oral Suspension contain aspartame which contains phenylalanine. Each 200 mg chewable tablet of Amoxicillin and Clavulanate Potassium contains 2.1 mg phenylalanine; each 400 mg chewable tablet contains 4.2 mg phenylalanine; each 5 mL of either the 200 mg/5 mL or 400 mg/5 mL oral suspension contains 7 mg phenylalanine. The other formulations of Amoxicillin and Clavulanate Potassium do not contain phenylalanine. 5.8 Development of Drug-Resistant Bacteria Prescribing Amoxicillin and Clavulanate Potassium in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug‑resistant bacteria."],"clinical_studies_table":["
Time Post Therapy875 mg every 12 hours % (n)500 mg every 8 hours % (n)
2 to 4 days81% (58)80% (54)
5 to 9 days58% (41)52% (52)
2 to 4 weeks 52% (101) 55% (104)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long‑term studies in animals have not been performed to evaluate carcinogenic potential. Amoxicillin and Clavulanate Potassium (4:1 ratio formulation of amoxicillin:clavulanate) was non-mutagenic in the Ames bacterial mutation assay, and the yeast gene conversion assay. Amoxicillin and Clavulanate Potassium was weakly positive in the mouse lymphoma assay, but the trend toward increased mutation frequencies in this assay occurred at doses that were also associated with decreased cell survival. Amoxicillin and Clavulanate Potassium was negative in the mouse micronucleus test, and in the dominant lethal assay in mice. Potassium clavulanate alone was tested in the Ames bacterial mutation assay and in the mouse micronucleus test, and was negative in each of these assays. Amoxicillin and Clavulanate Potassium (2:1 ratio formulation of amoxicillin:clavulanate) at oral doses of up to 1,200 mg/kg/day was found to have no effect on fertility and reproductive performance in rats. Based on body surface area, this dose of amoxicillin is approximately 4 times the maximum recommended adult human oral dose (875 mg every 12 hours). For clavulanate, the dose multiple is approximately 9 times higher than the maximum recommended adult human oral dose (125 mg every 8 hours), also based on body surface area."],"pharmacokinetics_table":["
a Mean (± standard deviation) values of 14 normal adults (N equals15 for clavulanate potassium in the low-dose regimens). Peak concentrations occurred approximately 1.5 hours after the dose.
b Amoxicillin and clavulanate potassium administered at the start of a light meal.
Dose and Regimen of Amoxicillin and ClavulanateCmax (mcg/mL)AUC0-24 (mcg*h/mL)
Amoxicillin and Clavulanate potassiumAmoxicillinClavulanate potassiumAmoxicillinClavulanate potassium
250 mg/125 mg every 8 hours 3.3 ± 1.121.5 ± 0.7026.7 ± 4.5612.6 ± 3.25
500 mg/125 mg every 12 hours 6.5 ± 1.411.8 ± 0.6133.4 ± 6.76 8.6 ± 1.95
500 mg/125 mg every 8 hours 7.2 ± 2.262.4 ± 0.8353.4 ± 8.8715.7 ± 3.86
875 mg/125 mg every 12 hours11.6 ± 2.782.2 ± 0.99 53.5 ± 12.3110.2 ± 3.04
","
Table 7: Mean (±S.D.) Amoxicillin and Clavulanate Potassium Pharmacokinetic Parametersa,b with Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets
a Mean (± standard deviation) values of 28 normal adults. Peak concentrations occurred approximately 1 hour after the dose.
b Amoxicillin and clavulanate potassium administered at the start of a light meal.
Dose of Amoxicillin and ClavulanateCmax (mcg/mL)AUC0-24 (mcg*h/mL)
Amoxicillin and Clavulanate potassiumAmoxicillinClavulanate potassiumAmoxicillinClavulanate potassium
400 mg/57 mg (5 mL of suspension)6.94 ± 1.241.10 ± 0.4217.29 ± 2.282.34 ± 0.94
400 mg/57 mg (1 chewable tablet)6.67 ± 1.371.03 ± 0.3317.24 ± 2.642.17 ± 0.73
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Administration Instructions Inform patients that Amoxicillin and Clavulanate Potassium may be taken every 8 hours or every 12 hours, depending on the dose prescribed. Each dose should be taken with a meal or snack to reduce the possibility of gastrointestinal upset. Allergic Reactions Counsel patients that Amoxicillin and Clavulanate Potassium contains a penicillin class drug product that can cause allergic reactions in some individuals. Severe Cutaneous Adverse Reactions (SCAR ) Advise patients about the signs and symptoms of serious skin manifestations. Instruct patients to stop taking Amoxicillin and Clavulanate Potassium immediately and promptly report the first signs or symptoms of skin rash, mucosal lesions, or any other sign of hypersensitivity [see Warnings and Precautions ( 5.2 )] . Diarrhea Counsel patients that diarrhea is a common problem caused by antibacterials, and it usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken their last dose of the antibacterial. If diarrhea is severe or lasts more than 2 or 3 days, patients should contact their physician as soon as possible. Antibacterial Resistance Patients should be counseled that antibacterial drugs, including Amoxicillin and Clavulanate Potassium, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Amoxicillin and Clavulanate Potassium is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Amoxicillin and Clavulanate Potassium or other antibacterial drugs in the future. Storage Instructions Advise patients to keep suspension refrigerated. Shake well before using. When dosing a child with the suspension (liquid) of Amoxicillin and Clavulanate Potassium, use a calibrated oral syringe. Be sure to rinse the calibrated oral syringe after each use. Bottles of suspension of Amoxicillin and Clavulanate Potassium may contain more liquid than required. Follow your doctor's instructions about the amount to use and the days of treatment your child requires. Discard any unused medicine. Manufactured By: USAntibiotics, LLC Bristol, TN 37620 (USA) AUGMENTIN is a registered trademark of GlaxoSmithKline and is licensed to USAntibiotics, LLC. CLINITEST is a registered trademark of Miles, Inc."],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Adults and Pediatric Patients greater than 40 kg: 500 or 875 mg every 12 hours or 250 or 500 mg every 8 hours, based on the amoxicillin component. ( 2.2 , 2.3 ) Pediatric patients aged 12 weeks (3 months) and older: 25 to 45 mg/kg/day every 12 hours or 20 to 40 mg/kg/day every 8 hours, up to the adult dose. ( 2.3 ) Neonates and infants less than 12 weeks of age: 30 mg/kg/day divided every 12 hours, based on the amoxicillin component. Use of the 125 mg/5 mL oral suspension is recommended. ( 2.3 ) 2.1 Important Administration Instructions Amoxicillin and Clavulanate Potassium may be taken without regard to meals; however, absorption of clavulanate potassium is enhanced when Amoxicillin and Clavulanate Potassium is administered at the start of a meal. To minimize the potential for gastrointestinal intolerance, Amoxicillin and Clavulanate Potassium should be taken at the start of a meal. 2.2 Adult Patients See dosing regimens of Amoxicillin and Clavulanate Potassium (based on the amoxicillin component) provided in Table 1 below. Table 1. Dosing Regimens of Amoxicillin and Clavulanate Potassium in Adult Patients TYPE OF INFECTION DOSING REGIMEN OF Amoxicillin and Clavulanate Potassium Severe infections and infections of the respiratory tract one 875 mg tablet a of Amoxicillin and Clavulanate Potassium every 12 hours or one 500 mg tablet b,c of Amoxicillin and Clavulanate Potassium every 8 hours Less severe infections one 500 mg tablet b,c of Amoxicillin and Clavulanate Potassium every 12 hours or one 250 mg tablet d of Amoxicillin and Clavulanate Potassium every 8 hours a Adults who have difficulty swallowing may be given the Amoxicillin and Clavulanate Potassium 200 mg/28.5 mg per 5 mL suspension or the Amoxicillin and Clavulanate Potassium 400 mg/57 mg per 5 mL suspension may be used in place of the 875 mg/125 mg tablet. b Adults who have difficulty swallowing may be given the Amoxicillin and Clavulanate Potassium 125 mg/31.25 mg per 5 mL or Amoxicillin and Clavulanate Potassium 250 mg/62.5 mg per 5 mL suspension in place of the 500 mg/125 mg tablet. c Two Amoxicillin and Clavulanate Potassium 250 mg/125 mg tablets are NOT substitutable with one 500 mg/125 mg Amoxicillin and Clavulanate Potassium tablet [see Dosage and Administration ( 2.6 )] . d Amoxicillin and Clavulanate Potassium 250 mg/125 mg tablet is NOT substitutable with Amoxicillin and Clavulanate Potassium 250 mg/62.5 mg chewable tablet [see Dosage and Administration ( 2.6 )] 2.3 Pediatric Patients Based on the amoxicillin component, Amoxicillin and Clavulanate Potassium should be dosed as follows: Neonates and Infants Aged less than 12 weeks (less than 3 months) : See dosing regimens of Amoxicillin and Clavulanate Potassium provided in Table 2 below. Table 2: Dosing Regimens of Amoxicillin and Clavulanate Potassium in Neonates and Infants Aged Less than 12 Weeks (Less than 3 Months) PATIENT POPULATION DOSING REGIMEN Amoxicillin and Clavulanate Potassium 125 mg/31.25 mg per 5 mL for oral suspension a Neonates and Infants aged less than 12 weeks (less than 3 months) 30 mg/kg/day every 12 hours a Experience with the Amoxicillin and Clavulanate Potassium 200 mg/28.5 mg per 5 mL formulation in this age group is limited, and thus, use of the Amoxicillin and Clavulanate Potassium 125 mg/31.25 mg per 5 mL for oral suspension is recommended. Patients Aged 12 weeks (3 months) and Older and Weighing Less than 40 kg : See dosing regimens provided in Table 3 below. The every 12 hour regimen is recommended as it is associated with significantly less diarrhea [see Clinical Studies ( 14.2 )] . The Amoxicillin and Clavulanate Potassium 200 mg/28.5 mg per 5 mL and Amoxicillin and Clavulanate Potassium 400 mg/57 mg per 5 mL) for oral suspension and Amoxicillin and Clavulanate Potassium 200 mg/28.5 mg and Amoxicillin and Clavulanate Potassium 400 mg/57 mg chewable tablets contain aspartame and should not be used by phenylketonurics. [see Warnings and Precautions ( 5.7 )]. Table 3: Dosing in Patients Aged 12 Weeks (3 Months) and Older and Weighing Less than 40 kg a Each strength of Amoxicillin and Clavulanate Potassium oral suspension is available as a chewable tablet for use by older children. b Duration of therapy studied and recommended for acute otitis media is 10 days. INFECTION DOSING REGIMEN Every 12 hours Every 8 hours Amoxicillin and Clavulanate Potassium 200 mg/28.5 mg per 5 mL or Amoxicillin and Clavulanate Potassium 400 mg/57 mg per 5 mL oral suspension a Amoxicillin and Clavulanate Potassium 125 mg/31.25 mg per 5 mL or Amoxicillin and Clavulanate Potassium 250 mg/62.5 mg per 5 mL oral suspension a Otitis media b , sinusitis, lower respiratory tract infections, and more severe infections 45 mg/kg/day every 12 hours 40 mg/kg/day every 8 hours Less severe infections 25 mg/kg/day every 12 hours 20 mg/kg/day every 8 hours Patients Weighing 40 kg or More : Pediatric patients weighing 40 kg or more should be dosed according to adult recommendations. The 250 mg/125 mg tablet of Amoxicillin and Clavulanate Potassium should NOT be used until the child weighs at least 40 kg, due to the different amoxicillin to clavulanic acid ratios in the 250 mg/125 mg tablet of Amoxicillin and Clavulanate Potassium versus the 250 mg/62.5 mg chewable tablet of Amoxicillin and Clavulanate Potassium. 2.4 Patients with Renal Impairment Patients with impaired renal function do not generally require a reduction in dose unless the impairment is severe. Renal impairment patients with a glomerular filtration rate (GFR) of less than 30 mL/min should NOT receive the 875 mg dose (based on the amoxicillin component) of Amoxicillin and Clavulanate Potassium. See dosing regimens in patients with severe renal impairment provided in Table 4. Table 4. Dosing Regimens of Amoxicillin and Clavulanate Potassium in Patients with Severe Renal Impairment Patients with Renal Impairment Dosing Regimen GFR 10 mL/min to 30 mL/min 500 mg or 250 mg every 12 hours, depending on the severity of the infection GFR less than 10 mL/min 500 mg or 250 mg every 24 hours, depending on severity of the infection Hemodialysis 500 mg or 250 mg every 24 hours, depending on severity of the infection Administer an additional dose both during and at the end of dialysis 2.5 Directions for Mixing Amoxicillin and Clavulanate Potassium for Oral Suspension Prepare Amoxicillin and Clavulanate Potassium for oral suspension at time of dispensing as follows: Tap bottle until all powder flows freely. Measure a total (see Table 5 below for total amount of water for reconstitution) OF WATER. Add approximately 2/3 of the water to the powder. Replace cap and shake VIGOROUSLY. Add remaining water. Replace cap and shake VIGOROUSLY. Table 5: Amount of Water for Mixing Amoxicillin and Clavulanate Potassium for Oral Suspension Strength of Amoxicillin and Clavulanate Potassiumfor Oral Suspension Bottle Size Amount of Water for Reconstitution Contents of Each Teaspoonful (5 mL) 125 mg/31.25 mg per 5 mL 75 mL 100 mL 150 mL 67 mL 90 mL 134 mL 125 mg of amoxicillin and 31.25 mg of clavulanic acid as the potassium salt 200 mg/28.5 mg per 5 mL 50 mL 75 mL 100 mL 50 mL 75 mL 95 mL 200 mg of amoxicillin and 28.5 mg of clavulanic acid as the potassium salt 250 mg/62.5 mg per 5 mL 75 mL 100 mL 150 mL 65 mL 87 mL 130 mL 250 mg of amoxicillin and 62.5 mg of clavulanic acid as the potassium salt 400 mg/57 mg per 5 mL 50 mL 75 mL 100 mL 50 mL 70 mL 90 mL 400 mg of amoxicillin and 57 mg of clavulanic acid as the potassium salt Shake oral suspension well before using. Reconstituted suspension must be stored under refrigeration and discarded after 10 days. Some color change is normal during dosing period. 2.6 Switching between Dosage Forms and between Strengths Amoxicillin and Clavulanate Potassium 250 mg/125 mg Tablet is NOT Substitutable with Amoxicillin and Clavulanate Potassium 250 mg/62.5 mg Chewable Tablet The 250 mg/125 mg tablet of Amoxicillin and Clavulanate Potassium and the 250 mg/62.5 mg chewable tablet of Amoxicillin and Clavulanate Potassium should NOT be substituted for each other and the 250 mg/125 mg tablet of Amoxicillin and Clavulanate Potassium should NOT be used in pediatric patients weighing less than 40 kg [see Dosage and Administration ( 2.3 )] . The 250 mg tablet of Amoxicillin and Clavulanate Potassium and the 250 mg chewable tablet of Amoxicillin and Clavulanate Potassium do not contain the same amount of clavulanic acid. The 250 mg tablet of Amoxicillin and Clavulanate Potassium contains 125 mg of clavulanic acid whereas the 250 mg chewable tablet of Amoxicillin and Clavulanate Potassium contains 62.5 mg of clavulanic acid. Two Amoxicillin and Clavulanate Potassium 250 mg/125 mg Tablets are NOT Substitutable with One 500 mg/125 mg Amoxicillin and Clavulanate Potassium Tablet Two 250 mg/125 mg tablets of Amoxicillin and Clavulanate Potassium should NOT be substituted for one 500 mg/125 mg tablet of Amoxicillin and Clavulanate Potassium. Since both the 250 mg and 500 mg tablets of Amoxicillin and Clavulanate Potassium contain the same amount of clavulanic acid (125 mg, as the potassium salt), two 250 mg tablets of Amoxicillin and Clavulanate Potassium are not equivalent to one 500 mg tablet of Amoxicillin and Clavulanate Potassium."],"spl_product_data_elements":["AMOXICILLIN AND CLAVULANATE POTASSIUM amoxicillin and clavulanate potassium AMOXICILLIN AMOXICILLIN ANHYDROUS CLAVULANATE POTASSIUM CLAVULANIC ACID SILICON DIOXIDE MICROCRYSTALLINE CELLULOSE SODIUM STARCH GLYCOLATE TYPE A POTATO MAGNESIUM STEARATE HYPROMELLOSE, UNSPECIFIED TITANIUM DIOXIDE POLYETHYLENE GLYCOL, UNSPECIFIED white capsule AUGMENTIN;875"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Amoxicillin and Clavulanate Potassium Tabl ets, USP : 250 mg/125 mg Tablets: Each white oval film-coated tablet, debossed with AUGMENTIN on one side and 250/125 on the other side, contains 250 mg of amoxicillin as the trihydrate and 125 mg of clavulanic acid as the potassium salt. 500 mg/125 mg Tablets : Each white oval film-coated tablet, debossed with AUGMENTIN on one side and 500/125 on the other side, contains 500 mg of amoxicillin as the trihydrate and 125 mg of clavulanic acid as the potassium salt. 875 mg/125 mg Tablets : Each scored white capsule‑shaped tablet, debossed with AUGMENTIN 875 on one side and scored on the other side, contains 875 mg of amoxicillin as the trihydrate and 125 mg of clavulanic acid as the potassium salt. Amoxicillin and Clavulanate Potassium for Oral Suspension, USP: 125 mg/31.25 mg per 5 mL : Banana-flavored powder for oral suspension (each 5 mL of reconstituted suspension contains 125 mg of amoxicillin as the trihydrate and 31.25 mg of clavulanic acid as the potassium salt). 200 mg/28.5 mg per 5 mL : Orange-flavored powder for oral suspension (each 5 mL of reconstituted suspension contains 200 mg of amoxicillin as the trihydrate and 28.5 mg of clavulanic acid as the potassium salt). 250 mg/62.5 mg per 5 mL : Orange-flavored powder for oral suspension (each 5 mL of reconstituted suspension contains 250 mg of amoxicillin as the trihydrate and 62.5 mg of clavulanic acid as the potassium salt). 400 mg/57 mg per 5 mL: Orange-flavored powder for oral suspension (each 5 mL of reconstituted suspension contains 400 mg of amoxicillin as the trihydrate and 57 mg of clavulanic acid as the potassium salt). Amoxicillin and Clavulanate Potassium Chewable Tablets, USP: 125 mg/31.25 mg Chewable Tablets : Each mottled yellow, round, lemon-lime-flavored tablet, debossed with BMP 189 contains 125 mg of amoxicillin as the trihydrate and 31.25 mg of clavulanic acid as the potassium salt. 200 mg/28.5 mg Chewable Tablets : Each mottled pink, round, biconvex cherry-banana-flavored tablet, debossed with AUGMENTIN 200 contains 200 mg of amoxicillin as the trihydrate and 28.5 mg of clavulanic acid as the potassium salt. 250 mg/62.5 mg Chewable Tablets : Each mottled yellow, round, lemon-lime-flavored tablet, debossed with BMP 190 contains 250 mg of amoxicillin as the trihydrate and 62.5 mg of clavulanic acid as the potassium salt. 400 mg/57 mg Chewable Tablets : Each mottled pink, round, biconvex cherry-banana-flavored tablet, debossed with AUGMENTIN 400 contains 400 mg of amoxicillin as the trihydrate and 57 of clavulanic acid as the potassium salt. Tablets: 250 mg/125 mg, 500 mg/125 mg, 875 mg/125 mg; 875 mg/125 mg tablets are scored. ( 3 ) For Oral Suspension: 125 mg/31.25 mg per 5 mL, 200 mg/28.5 mg per 5 mL, 250 mg/62.5 mg per 5 mL, 400 mg/57 mg per 5 mL ( 3 ) Chewable Tablets: 125 mg/31.25 mg, 200 mg/28.5 mg, 250 mg/62.5 mg, 400 mg/57 mg ( 3 )"],"recent_major_changes_table":["
Warnings and Precautions (5)8/2022
"],"clinical_pharmacology_table":["
a Mean (± standard deviation) values of 14 normal adults (N equals15 for clavulanate potassium in the low-dose regimens). Peak concentrations occurred approximately 1.5 hours after the dose.
b Amoxicillin and clavulanate potassium administered at the start of a light meal.
Dose and Regimen of Amoxicillin and ClavulanateCmax (mcg/mL)AUC0-24 (mcg*h/mL)
Amoxicillin and Clavulanate potassiumAmoxicillinClavulanate potassiumAmoxicillinClavulanate potassium
250 mg/125 mg every 8 hours 3.3 ± 1.121.5 ± 0.7026.7 ± 4.5612.6 ± 3.25
500 mg/125 mg every 12 hours 6.5 ± 1.411.8 ± 0.6133.4 ± 6.76 8.6 ± 1.95
500 mg/125 mg every 8 hours 7.2 ± 2.262.4 ± 0.8353.4 ± 8.8715.7 ± 3.86
875 mg/125 mg every 12 hours11.6 ± 2.782.2 ± 0.99 53.5 ± 12.3110.2 ± 3.04
","
Table 7: Mean (±S.D.) Amoxicillin and Clavulanate Potassium Pharmacokinetic Parametersa,b with Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets
a Mean (± standard deviation) values of 28 normal adults. Peak concentrations occurred approximately 1 hour after the dose.
b Amoxicillin and clavulanate potassium administered at the start of a light meal.
Dose of Amoxicillin and ClavulanateCmax (mcg/mL)AUC0-24 (mcg*h/mL)
Amoxicillin and Clavulanate potassiumAmoxicillinClavulanate potassiumAmoxicillinClavulanate potassium
400 mg/57 mg (5 mL of suspension)6.94 ± 1.241.10 ± 0.4217.29 ± 2.282.34 ± 0.94
400 mg/57 mg (1 chewable tablet)6.67 ± 1.371.03 ± 0.3317.24 ± 2.642.17 ± 0.73
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Pediatric Use: Modify dose in patients 12 weeks or younger. ( 8.4 ) Renal Impairment: Dosage adjustment is recommended for severe renal impairment (GFR less than 30mL/min). ( 2.4 , 8.6 ) Revised 03/2024 8.1 Pregnancy Teratogenic Effects : Pregnancy Category B. Reproduction studies performed in pregnant rats and mice given Amoxicillin and Clavulanate Potassium (2:1 ratio formulation of amoxicillin:clavulanate) at oral doses up to 1200 mg/kg/day revealed no evidence of harm to the fetus due to Amoxicillin and Clavulanate Potassium. The amoxicillin doses in rats and mice (based on body surface area) were approximately 4 and 2 times the maximum recommended adult human oral dose (875 mg every 12 hours). For clavulanate, these dose multiples were approximately 9 and 4 times the maximum recommended adult human oral dose (125 mg every 8 hours). There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. 8.2 Labor and Delivery Oral ampicillin‑class antibacterials are poorly absorbed during labor. It is not known whether use of amoxicillin and clavulanate potassium in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood of the necessity for an obstetrical intervention. 8.3 Nursing Mothers Amoxicillin has been shown to be excreted in human milk. Amoxicillin and clavulanate potassium use by nursing mothers may lead to sensitization of infants. Caution should be exercised when amoxicillin and clavulanate potassium is administered to a nursing woman. 8.4 Pediatric Use The safety and effectiveness of Amoxicillin and Clavulanate Potassium for Oral Suspension and Chewable Tablets have been established in pediatric patients. Use of Amoxicillin and Clavulanate Potassium in pediatric patients is supported by evidence from studies of Amoxicillin and Clavulanate Potassium Tablets in adults with additional data from a study of Amoxicillin and Clavulanate Potassium for Oral Suspension in pediatric patients aged 2 months to 12 years with acute otitis media [see Clinical Studies ( 14.2 )] . Because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed; clavulanate elimination is unaltered in this age group. Dosing of Amoxicillin and Clavulanate Potassium should be modified in pediatric patients aged less than 12 weeks (less than 3 months) [see Dosage and Administration ( 2.3 )]. 8.5 Geriatric Use Of the 3,119 patients in an analysis of clinical studies of Amoxicillin and Clavulanate Potassium, 32% were greater than or equal to 65 years old, and 14% were greater than or equal to 75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. 8.6 Renal Impairment Amoxicillin is primarily eliminated by the kidney and dosage adjustment is usually required in patients with severe renal impairment (GFR less than 30 mL/min). See Patients with Renal Impairment [see Dosage and Administration ( 2.4 )] for specific recommendations in patients with renal impairment."],"dosage_and_administration_table":["
TYPE OF INFECTIONDOSING REGIMEN OF Amoxicillin and Clavulanate Potassium
Severe infections and infections of the respiratory tractone 875 mg tableta of Amoxicillin and Clavulanate Potassium every 12 hours or one 500 mg tabletb,c of Amoxicillin and Clavulanate Potassium every 8 hours
Less severe infections one 500 mg tabletb,c of Amoxicillin and Clavulanate Potassium every 12 hours or one 250 mg tabletd of Amoxicillin and Clavulanate Potassium every 8 hours
","
PATIENT POPULATIONDOSING REGIMEN
Amoxicillin and Clavulanate Potassium 125 mg/31.25 mg per 5 mL for oral suspensiona
Neonates and Infants aged less than 12weeks (less than 3 months) 30 mg/kg/day every 12 hours
","
a Each strength of Amoxicillin and Clavulanate Potassium oral suspension is available as a chewable tablet for use by older children.
b Duration of therapy studied and recommended for acute otitis media is 10 days.
INFECTIONDOSING REGIMEN
Every 12 hoursEvery 8 hours
Amoxicillin and Clavulanate Potassium 200 mg/28.5 mg per 5 mL orAmoxicillin and Clavulanate Potassium 400 mg/57 mg per 5 mL oral suspensionaAmoxicillin and Clavulanate Potassium 125 mg/31.25 mg per 5 mL orAmoxicillin and Clavulanate Potassium 250 mg/62.5 mg per 5 mL oral suspensiona
Otitis mediab, sinusitis, lower respiratory tract infections, and more severe infections45 mg/kg/day every 12 hours40 mg/kg/day every 8 hours
Less severe infections25 mg/kg/day every 12 hours20 mg/kg/day every 8 hours
","
Patients with Renal ImpairmentDosing Regimen
GFR 10 mL/min to 30 mL/min 500 mg or 250 mg every 12 hours, dependingon the severity of the infection
GFR less than 10 mL/min 500 mg or 250 mg every 24 hours, dependingon severity of the infection
Hemodialysis 500 mg or 250 mg every 24 hours, dependingon severity of the infection Administer an additional dose both duringand at the end of dialysis
","
Strength of Amoxicillin and Clavulanate Potassiumfor Oral SuspensionBottle SizeAmount of Water for ReconstitutionContents of Each Teaspoonful (5 mL)
125 mg/31.25 mgper 5 mL75 mL 100 mL 150 mL 67 mL 90 mL 134 mL125 mg of amoxicillin and 31.25 mg of clavulanic acid as the potassium salt
200 mg/28.5 mgper 5 mL50 mL 75 mL 100 mL 50 mL 75 mL 95 mL200 mg of amoxicillin and 28.5 mg of clavulanic acid as the potassium salt
250 mg/62.5 mgper 5 mL75 mL 100 mL 150 mL 65 mL 87 mL 130 mL250 mg of amoxicillin and 62.5 mg of clavulanic acid as the potassium salt
400 mg/57 mgper 5 mL50 mL 75 mL 100 mL 50 mL 70 mL 90 mL400 mg of amoxicillin and 57 mg of clavulanic acid as the potassium salt
"],"package_label_principal_display_panel":["AMOXICILLIN AND CLAVULANATE POTASSIUM Label Image"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long‑term studies in animals have not been performed to evaluate carcinogenic potential. Amoxicillin and Clavulanate Potassium (4:1 ratio formulation of amoxicillin:clavulanate) was non-mutagenic in the Ames bacterial mutation assay, and the yeast gene conversion assay. Amoxicillin and Clavulanate Potassium was weakly positive in the mouse lymphoma assay, but the trend toward increased mutation frequencies in this assay occurred at doses that were also associated with decreased cell survival. Amoxicillin and Clavulanate Potassium was negative in the mouse micronucleus test, and in the dominant lethal assay in mice. Potassium clavulanate alone was tested in the Ames bacterial mutation assay and in the mouse micronucleus test, and was negative in each of these assays. Amoxicillin and Clavulanate Potassium (2:1 ratio formulation of amoxicillin:clavulanate) at oral doses of up to 1,200 mg/kg/day was found to have no effect on fertility and reproductive performance in rats. Based on body surface area, this dose of amoxicillin is approximately 4 times the maximum recommended adult human oral dose (875 mg every 12 hours). For clavulanate, the dose multiple is approximately 9 times higher than the maximum recommended adult human oral dose (125 mg every 8 hours), also based on body surface area."]},"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"probenecid","severity":"major","mechanism":"Probenecid decreases the renal tubular secretion of amoxicillin but does not delay renal excretion of clavulanic acid.","management":"Co-administration with probenecid is not recommended.","clinicalEffect":"Increased and prolonged blood concentrations of amoxicillin."},{"drug":"oral anticoagulants","severity":"major","mechanism":"Amoxicillin and Clavulanate Potassium may interact with oral anticoagulants.","management":"Appropriate monitoring should be undertaken. Adjustments in the dose of oral anticoagulants may be necessary.","clinicalEffect":"Abnormal prolongation of prothrombin time (increased INR)."},{"drug":"allopurinol","severity":"moderate","mechanism":"The concurrent administration of allopurinol and amoxicillin increases the incidence of rashes.","management":"Monitor for rash development.","clinicalEffect":"Increased incidence of rashes."},{"drug":"oral contraceptives","severity":"moderate","mechanism":"Amoxicillin and Clavulanate Potassium may affect intestinal flora, leading to lower estrogen reabsorption.","management":"Consider alternative contraceptive methods or monitor for contraceptive failure.","clinicalEffect":"Reduced efficacy of combined oral estrogen/progesterone contraceptives."}],"commonSideEffects":[{"effect":"diarrhea/loose stools","drugRate":"9%","_validated":true,"placeboRate":""},{"effect":"nausea","drugRate":"3%","_validated":true,"placeboRate":""},{"effect":"skin rashes and urticaria","drugRate":"3%","_validated":true,"placeboRate":""},{"effect":"vomiting","drugRate":"1%","_validated":true,"placeboRate":""},{"effect":"vaginitis","drugRate":"1%","_validated":true,"placeboRate":""}],"contraindications":["History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to Amoxicillin and Clavulanate Potassium or to other beta-lactams (e.g., penicillins or cephalosporins).","History of cholestatic jaundice/hepatic dysfunction associated with Amoxicillin and Clavulanate Potassium."],"discontinuationRates":[{"trial":"","drugArm":"<3%","placeboArm":"","commonReason":"drug-related adverse reactions"}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Amoxicillin and clavulanate","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:04:04.594585+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T05:05:26.826197+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:04:10.861065+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Amoxicillin and clavulanate","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:04:11.245079+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:04:03.479045+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:05:21.191106+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:04:03.479077+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action Amoxicillin and Clavulanate Potassium is an antibacterial drug [see Microbiology ( 12.4 )] .","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:04:17.935192+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:04:57.688097+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2105950/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:04:12.393688+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS The following are discussed in more detail in other sections of the labeling: Anaphylactic reactions [see Warnings and Precautions (5.1) ] Severe Cutaneous Adverse Reactions [see Warnings and Precautions ( 5.2 )] Hepatic Dysfunction [see Warnings and Precautions (5.3) ] Clostridioides difficile Associated Diarrhea (CDAD) [see Warnings and Precautions (5.4) ] The most frequently reported adverse effects were diarrhea/loose stools (9%), nausea (3%), skin rashes and urticaria (3","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:04:28.107872+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:04:33.776103+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA050720","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:04:03.479082+00:00"}},"_dailymed":{"setId":"a26f2ceb-bb9b-4813-9691-634338186860","title":"AMOXICILLIN AND CLAVULANATE POTASSIUM TABLET, FILM COATED [REMEDYREPACK INC.]"},"aiSummary":"Amoxicillin and Clavulanate, marketed by GlaxoSmithKline, is a well-established antibacterial drug primarily indicated for lower respiratory tract infections. The drug's key strength lies in its combination of amoxicillin and clavulanate potassium, which enhances its efficacy against a broad spectrum of bacteria. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.","mechanism":{"oneSentence":"Amoxicillin and Clavulanate Potassium is an antibacterial drug."},"_scrapedAt":"2026-03-28T04:09:04.699Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T05:05:26.826671+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"id":"amoxicillin-and-clavulanate-lower-respiratory-tract-infect","name":"Lower Respiratory Tract Infections","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adults and pediatric patients","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adults and pediatric patients","diagnosticRequired":null,"brandNameForIndication":""},{"id":"amoxicillin-and-clavulanate-acute-bacterial-otitis-media","name":"Acute Bacterial Otitis Media","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adults and pediatric patients","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adults and pediatric patients","diagnosticRequired":null,"brandNameForIndication":""},{"id":"amoxicillin-and-clavulanate-sinusitis","name":"Sinusitis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adults and pediatric patients","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adults and pediatric patients","diagnosticRequired":null,"brandNameForIndication":""},{"id":"amoxicillin-and-clavulanate-skin-and-skin-structure-infect","name":"Skin and Skin Structure Infections","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adults and pediatric patients","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adults and pediatric patients","diagnosticRequired":null,"brandNameForIndication":""},{"id":"amoxicillin-and-clavulanate-urinary-tract-infections","name":"Urinary Tract Infections","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adults and pediatric patients","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adults and pediatric patients","diagnosticRequired":null,"brandNameForIndication":""}]},"trialDetails":[{"nctId":"NCT07483736","phase":"PHASE3","title":"Efficacy of an Empirical Treatment With Amoxicillin-clavulanate (AC) Compared to the Combination Amoxicillin-clavulanate and Ciprofloxacin (AC+C) in the Outpatient Care of Chemotherapy-induced Fever in Adult Haematology Patients.","status":"NOT_YET_RECRUITING","sponsor":"Versailles Hospital","startDate":"2026-03","conditions":"C15.378","enrollment":1526},{"nctId":"NCT07322549","phase":"","title":"Amoxicillin/Clavulanic Acid Susceptibility in Acute Community-acquired Pneumonia Requiring Intensive Care Management","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","startDate":"2025-03-01","conditions":"Severe Community-acquired Pneumonia","enrollment":104},{"nctId":"NCT07451171","phase":"PHASE2","title":"Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2026-04","conditions":"Small Intestine Bacterial Overgrowth","enrollment":60},{"nctId":"NCT06076304","phase":"PHASE4","title":"Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis","status":"RECRUITING","sponsor":"Daniel Merenstein","startDate":"2023-11-21","conditions":"Sinus Infection, Acute Sinusitis","enrollment":3720},{"nctId":"NCT06494072","phase":"PHASE4","title":"Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2024-08-22","conditions":"Community Acquired Pneumonia in Children","enrollment":236},{"nctId":"NCT06537609","phase":"NA","title":"A Platform Trial for Gram Negative Bloodstream Infections","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2024-04-24","conditions":"Gram-negative Bacteremia","enrollment":2500},{"nctId":"NCT05100654","phase":"EARLY_PHASE1","title":"Collaborative Urological Prosthetics Investigation Directive Research Group","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2022-04-22","conditions":"Erectile Dysfunction, Penile Prosthesis Infection","enrollment":800},{"nctId":"NCT07364253","phase":"NA","title":"'Propolis Versus Chlorhexidine Gluconate on Wound Healing After Third Molar Surgery: a Randomized Controlled Trial'","status":"COMPLETED","sponsor":"Ataturk University","startDate":"2021-01-05","conditions":"Third Molar Surgery, Post Operative Analgesia","enrollment":52},{"nctId":"NCT06229288","phase":"PHASE3","title":"Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-04-25","conditions":"Community-acquired Pneumonia","enrollment":326},{"nctId":"NCT07030673","phase":"NA","title":"Early Discontinuation of Antibiotic Therapy in Elderly Patients Hospitalized for a Viral Infection","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2025-02-14","conditions":"Elderly, Antibiotics Overuse, Viral Infections","enrollment":256},{"nctId":"NCT02456974","phase":"","title":"Antibiotic Dosing in Pediatric Intensive Care","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2012-05","conditions":"Pharmacokinetics, Amoxicillin-clavulanate, Piperacillin-tazobactam","enrollment":640},{"nctId":"NCT06426836","phase":"NA","title":"Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2016-08-19","conditions":"Pharmacokinetics, Amoxicillin-clavulanate, Piperacillin-tazobactam","enrollment":300},{"nctId":"NCT04549311","phase":"PHASE3","title":"Perianal Abscess Recurrence and Fistula Formation: Antibiotics Following Incision and Drainage Trial","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2021-11-18","conditions":"Perianal Abscess, Perianal Fistula","enrollment":15},{"nctId":"NCT05079620","phase":"PHASE4","title":"Early Antibiotics After Aspiration in ICU Patients","status":"TERMINATED","sponsor":"UConn Health","startDate":"2021-11-30","conditions":"Aspiration, Aspiration Pneumonia","enrollment":5},{"nctId":"NCT02281929","phase":"PHASE3","title":"Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2015-06-13","conditions":"Alcoholic Hepatitis, Alcoholic Liver Disease","enrollment":297},{"nctId":"NCT01388413","phase":"PHASE4","title":"Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2011-08","conditions":"Neurogenic Bladder, Urinary Tract Infection","enrollment":45},{"nctId":"NCT07236944","phase":"PHASE4","title":"Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2025-12","conditions":"Febrile Urinary Tract Infection","enrollment":560},{"nctId":"NCT06294600","phase":"PHASE3","title":"Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)","status":"RECRUITING","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2024-02-12","conditions":"Community-acquired Pneumonia","enrollment":330},{"nctId":"NCT07269171","phase":"NA","title":"The Effect of Supplementary Foods Containing Trypsin, Chymotrypsin and Serratia Peptidase on Healing After Impacted Wisdom Tooth Surgery","status":"NOT_YET_RECRUITING","sponsor":"Saglik Bilimleri Universitesi","startDate":"2025-12-01","conditions":"Oral Health Care","enrollment":15},{"nctId":"NCT04350502","phase":"NA","title":"Pharmacokinetics and Pleural Fluid Penetration of Amoxicillin and Clavulanic Acid in Patients With Pleural Infections","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2019-07-18","conditions":"Pleural Infection, Empyema, Community-acquired Pneumonia","enrollment":11},{"nctId":"NCT07234448","phase":"NA","title":"Evaluation of the Use of a Probiotic Containing Bifidobacterium Breve PRL2020 in Oral Drops in Preventing Side Effects From Amoxicillin or Amoxicillin/Clavulanic Acid Antibiotic Use","status":"NOT_YET_RECRUITING","sponsor":"Liaquat University of Medical & Health Sciences","startDate":"2025-12-01","conditions":"Antibiotic-associated Diarrhea","enrollment":1000},{"nctId":"NCT05840588","phase":"NA","title":"Effect of Bifidobacterium Breve PRL2020 (an Amoxicillin-clavulanate-resistant Strain) on Gastrointestinal Symptoms and Gut Microbiota Composition in Children Treated With Amoxicillin or Amoxicillin/Clavulanate","status":"COMPLETED","sponsor":"Liaquat University of Medical & Health Sciences","startDate":"2023-11-06","conditions":"Bacterial Infections","enrollment":121},{"nctId":"NCT01543334","phase":"","title":"Antibiotic Concentrations Among Critically Ill Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2012-03","conditions":"Administration of Antibiotics in Intensive Care Units","enrollment":98},{"nctId":"NCT07233733","phase":"NA","title":"A Clinical Study of Connective Tissue Graft and Enamel Matrix Derivative in the Treatment of Intrabony Periodontal Defects","status":"COMPLETED","sponsor":"Phạm Đình Thiên Khải","startDate":"2024-06-01","conditions":"Periodontal Diseases, Regeneration","enrollment":17},{"nctId":"NCT05846399","phase":"PHASE4","title":"CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)","status":"RECRUITING","sponsor":"University of Missouri-Columbia","startDate":"2023-09-07","conditions":"Cat Bite, Hand Injuries, Arm Injury","enrollment":72},{"nctId":"NCT07202091","phase":"PHASE2, PHASE3","title":"Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)","status":"RECRUITING","sponsor":"Monash University","startDate":"2025-05-06","conditions":"Myeloma, Leukemia, Non Hodgkin's Lymphoma","enrollment":900},{"nctId":"NCT07202052","phase":"PHASE2, PHASE3","title":"Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)","status":"RECRUITING","sponsor":"Monash University","startDate":"2025-05-06","conditions":"Myeloma, Non-Hodgkin's Lymphoma, Leukemia","enrollment":900},{"nctId":"NCT07104370","phase":"NA","title":"Freeze-dried Bone Allograft vs Autologous Bone Blocks in the Lateral Augmentation of the Jaws","status":"RECRUITING","sponsor":"Semmelweis University","startDate":"2025-09-29","conditions":"Edentulous Alveolar Ridge, Edentulous Alveolar Ridge Atrophy","enrollment":30},{"nctId":"NCT01015417","phase":"PHASE3","title":"Place of Antibiotics in the Postoperative Acute Lithiasic Cholecystitis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2010-05","conditions":"Acute Lithiasic Cholecystitis Grade I or II, Symptoms Lasting for Less Than 5 Days, Required Cholecystectomy","enrollment":414},{"nctId":"NCT06443502","phase":"PHASE3","title":"A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-11-19","conditions":"Pouchitis","enrollment":30},{"nctId":"NCT06055257","phase":"PHASE3","title":"Combination Therapy: Hyperbaric Oxygen and PENTOCLO for Treatment of Osteoradionecrosis of the Mandible","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2025-01-16","conditions":"Osteoradionecrosis, Osteoradionecrosis of Jaw, Osteoradionecrosis of the Mandible","enrollment":24},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT07082465","phase":"","title":"Epidemiology of Antimicrobial-use and Antimicrobial-resistant Infections in Four Hospitals in Thailand","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2025-08-01","conditions":"Drug Resistance, Bacterial, Bacteremia","enrollment":108000},{"nctId":"NCT06804096","phase":"PHASE4","title":"Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)","status":"RECRUITING","sponsor":"Dr. Md. Alimur Reza","startDate":"2025-02-20","conditions":"Pneumonia, Community-Acquired, Bacterial Pneumonia","enrollment":160},{"nctId":"NCT04198129","phase":"PHASE1","title":"The Evaluation of Postoperative Antibiotics in Non-Infected Mandible Fractures","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2020-10-01","conditions":"Jaw Fractures, Infection","enrollment":13},{"nctId":"NCT03130452","phase":"PHASE4","title":"Helicobacter Pylori Eradication Study","status":"COMPLETED","sponsor":"Inje University","startDate":"2016-12-17","conditions":"Helicobacter Pylori Infection","enrollment":423},{"nctId":"NCT06953271","phase":"PHASE4","title":"Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection","status":"NOT_YET_RECRUITING","sponsor":"Women and Infants Hospital of Rhode Island","startDate":"2025-05-15","conditions":"Overactive Bladder (OAB), Urinary Tract Infection (Diagnosis)","enrollment":164},{"nctId":"NCT06929702","phase":"PHASE4","title":"Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2025-04-22","conditions":"Amoxicillin-clavulanate, Piperacillin-tazobactam, Meropenem","enrollment":58},{"nctId":"NCT04563325","phase":"PHASE4","title":"Oral-only Antibiotics for Bone and Joint Infections in Children","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2020-09-15","conditions":"Osteomyelitis, Septic Arthritis, Bone Infection","enrollment":180},{"nctId":"NCT06827496","phase":"","title":"Initial Oral Antibiotics for Bone and Joint Infections in Children","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2024-11-15","conditions":"Osteomyelitis Acute, Septic Arthritis, Bone Infection","enrollment":100},{"nctId":"NCT06895135","phase":"NA","title":"Comparison of Amoxicillin and Amoxicillin + Clavulanic Acid in Treating Acute Otitis Media in Children","status":"NOT_YET_RECRUITING","sponsor":"University of Health Sciences Lahore","startDate":"2025-05","conditions":"Acute Otitis Media","enrollment":162},{"nctId":"NCT05340257","phase":"PHASE2","title":"A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2023-10-14","conditions":"Infections, Bacterial","enrollment":""},{"nctId":"NCT06850714","phase":"NA","title":"Evaluation of Bifidobacterium Breve PRL2020 in Preventing Antibiotic-Associated Side Effects From Amoxicillin or Amoxicillin/Clavulanic Acid","status":"NOT_YET_RECRUITING","sponsor":"Liaquat University of Medical & Health Sciences","startDate":"2025-02-23","conditions":"Antibiotic Side Effect","enrollment":800},{"nctId":"NCT04414722","phase":"EARLY_PHASE1","title":"Mechanisms of Probiotics and Antibiotic-Associated Diarrhea","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2021-01-01","conditions":"Antibiotic-associated Diarrhea","enrollment":118},{"nctId":"NCT04048304","phase":"NA","title":"Short Post-surgical Antibiotic Therapy in Spine Infections - a Prospective, Randomized, Unblinded, Non-inferiority Trial","status":"RECRUITING","sponsor":"Balgrist University Hospital","startDate":"2019-07-31","conditions":"Infection","enrollment":236},{"nctId":"NCT05584683","phase":"PHASE1","title":"A Pharmacokinetic Study of LP-001 in Children With a Bacterial Infection","status":"COMPLETED","sponsor":"Kaizen Bioscience Co.","startDate":"2023-08-09","conditions":"Pediatric, Bacterial Infections","enrollment":39},{"nctId":"NCT02365623","phase":"PHASE2","title":"An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2015-02-18","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":6},{"nctId":"NCT05553743","phase":"","title":"Researchers At UC San Diego Are Learning About the Benefits of Human Milk and How It Influences Infant and Child Health","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2014-03-27","conditions":"Breastfeeding, COVID-19 Infection, COVID-19 Vaccine","enrollment":5000},{"nctId":"NCT06787027","phase":"NA","title":"Effect of Manual Massage Technique on Swelling, Pain and Mouth Opening After Bilateral Lower Third Molar Surgery","status":"COMPLETED","sponsor":"Izmir Katip Celebi University","startDate":"2018-03-01","conditions":"Impacted Third Molar Tooth, Swelling/ Edema, Pain","enrollment":46},{"nctId":"NCT06709196","phase":"PHASE4","title":"Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2025-01-07","conditions":"Cystectomy, Bladder Cancer Requiring Cystectomy, Postoperative Infections","enrollment":248},{"nctId":"NCT06020716","phase":"PHASE4","title":"Antibiotics, Microbiology and Immunology in Children With Chronic Wet Cough - the AMIC Study","status":"RECRUITING","sponsor":"Helse Stavanger HF","startDate":"2023-08-16","conditions":"Protracted Bacterial Bronchitis","enrollment":350},{"nctId":"NCT05830162","phase":"PHASE4","title":"Oral Antibiotics After Obstetric Perineal Tear","status":"COMPLETED","sponsor":"Hanna Jangö","startDate":"2023-03-21","conditions":"Obstetric Trauma, Infections, Wound Dehiscence","enrollment":442},{"nctId":"NCT06533397","phase":"NA","title":"The Application of a Biphasic Calcium Sulfate Graft Material in Sinus Floor Elevation","status":"RECRUITING","sponsor":"Semmelweis University","startDate":"2024-08-24","conditions":"Alveolar Bone Loss, Edentulism Nos","enrollment":40},{"nctId":"NCT05584657","phase":"PHASE3","title":"Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women","status":"COMPLETED","sponsor":"Iterum Therapeutics, International Limited","startDate":"2022-10-18","conditions":"Urinary Tract Infections, Cystitis","enrollment":2229},{"nctId":"NCT04803422","phase":"NA","title":"Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis.","status":"COMPLETED","sponsor":"Zealand University Hospital","startDate":"2021-04-01","conditions":"Complicated Appendicitis","enrollment":3193},{"nctId":"NCT05893147","phase":"NA","title":"BALANCE+ Vanguard Phase","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2023-08-26","conditions":"Gram-negative Bacteremia","enrollment":174},{"nctId":"NCT05753735","phase":"PHASE2","title":"eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF","status":"TERMINATED","sponsor":"Case Comprehensive Cancer Center","startDate":"2024-01-18","conditions":"Pancreatic Fistula","enrollment":3},{"nctId":"NCT04436991","phase":"","title":"Antibiotic Dosing in Geriatric Patients At the Emergency Department","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2018-01-03","conditions":"Elderly Infection, Frailty, Frail Elderly Syndrome","enrollment":180},{"nctId":"NCT05804123","phase":"NA","title":"LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media","status":"COMPLETED","sponsor":"Anabio R&D","startDate":"2021-10-28","conditions":"Upper Respiratory Tract Infections","enrollment":175},{"nctId":"NCT00836901","phase":"PHASE1","title":"Amoxicillin-Clavulanic Acid 400 Mg-57 mg Chewable Tablets Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-09","conditions":"Healthy","enrollment":52},{"nctId":"NCT00835705","phase":"PHASE1","title":"Amoxicillin-Clavulanic Acid 400 Mg-57 mg Chewable Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-09","conditions":"Healthy","enrollment":52},{"nctId":"NCT04755179","phase":"","title":"Identification of the Optimal Treatment Strategy for Complex Appendicitis in the Pediatric Population","status":"COMPLETED","sponsor":"Ramon Gorter","startDate":"2019-08-12","conditions":"Appendicitis, Appendix Mass, Appendicitis Perforated","enrollment":1308},{"nctId":"NCT06502288","phase":"NA","title":"Evaluation of Antibiotic Administration Following Tooth Extraction","status":"NOT_YET_RECRUITING","sponsor":"Chittagong Medical College","startDate":"2025-01-01","conditions":"Tooth Extraction","enrollment":152},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT05819229","phase":"","title":"Oral Antibiotics Alone in Children Aged 4 Weeks to 2 Months With a Urinary Tract Infection","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2023-02-27","conditions":"Urinary Tract Infections in Children","enrollment":125},{"nctId":"NCT04041791","phase":"PHASE3","title":"A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-08-19","conditions":"Pneumonia","enrollment":4392},{"nctId":"NCT06458478","phase":"NA","title":"Effects of the Application of a Hyper-oxygenated Gel After Oral Surgery","status":"RECRUITING","sponsor":"Azienda Ospedaliera di Perugia","startDate":"2024-07-01","conditions":"Molar, Fourth, Extracting Own Teeth, Edema Face","enrollment":72},{"nctId":"NCT06277609","phase":"PHASE1","title":"A Trial Investigating Lu AF28996 in Healthy Adult Participants","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2024-02-27","conditions":"Healthy Participants","enrollment":22},{"nctId":"NCT04600752","phase":"PHASE4","title":"Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-05-07","conditions":"Otitis Media, Infections, Respiratory Tract, Respiratory Tract Infections","enrollment":310},{"nctId":"NCT00423176","phase":"PHASE3","title":"The Study of Nasonex® Compared With Placebo for the Relief of Symptoms Associated With Acute Bacterial Sinusitis When Used With Antibiotics (Study P04824AM3)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2006-12","conditions":"Sinusitis","enrollment":237},{"nctId":"NCT05169554","phase":"PHASE2","title":"Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy","status":"RECRUITING","sponsor":"Fundacion Agencia Aragonesa para la Investigacion y Desarrollo (ARAID)","startDate":"2021-12-01","conditions":"Buruli Ulcer","enrollment":140},{"nctId":"NCT05678621","phase":"PHASE2, PHASE3","title":"Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension","status":"RECRUITING","sponsor":"Monash University","startDate":"2022-11-30","conditions":"Haematological Malignancy, Hypogammaglobulinemia","enrollment":300},{"nctId":"NCT04573504","phase":"PHASE4","title":"Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2020-09-23","conditions":"Vaginal Laceration During Delivery","enrollment":274},{"nctId":"NCT05519072","phase":"PHASE4","title":"Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA","status":"RECRUITING","sponsor":"Atlantic Health System","startDate":"2022-08-16","conditions":"Antibiotic Prophylaxis","enrollment":140},{"nctId":"NCT05999955","phase":"NA","title":"Safety and Efficacy of DSM 32444 Postbiotic in the Treatment of Acute Rhinosinusitis","status":"COMPLETED","sponsor":"Huro Biotech Joint Stock Company","startDate":"2022-12-29","conditions":"Rhinosinusitis, Rhinitis","enrollment":60},{"nctId":"NCT03897582","phase":"","title":"Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy: the BLIPIC Study","status":"RECRUITING","sponsor":"Centre Hospitalier de Valenciennes","startDate":"2019-02-22","conditions":"Beta-lactam, Continuous Renal Replacement Therapy, Pneumonia","enrollment":65},{"nctId":"NCT05248620","phase":"NA","title":"Prophylactic Antibiotic Treatment in Hemodialysis","status":"RECRUITING","sponsor":"Zealand University Hospital","startDate":"2022-02-14","conditions":"Hemodialysis","enrollment":800},{"nctId":"NCT06193837","phase":"","title":"Prophylactic Antibiotic in Non-complicated Low Risk Lap Cholecystectomy (LC)","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2024-01-01","conditions":"Cholecystectomy, Laparoscopic","enrollment":200},{"nctId":"NCT06154720","phase":"","title":"Surgical Site Infection After Episiotomy Repair Related to Routine Use of Antibiotic Prophylaxis in Low-Risk Population","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-09-10","conditions":"Surgical Site Infection","enrollment":200},{"nctId":"NCT03508921","phase":"PHASE4","title":"Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-07-01","conditions":"Overactive Bladder, Urinary Tract Infections","enrollment":22},{"nctId":"NCT02848820","phase":"PHASE4","title":"Initial Non-operative Treatment Strategy Versus Appendectomy Treatment Strategy for Simple Appendicitis in Children","status":"UNKNOWN","sponsor":"Ramon Gorter","startDate":"2016-12","conditions":"Appendicitis","enrollment":302},{"nctId":"NCT02021006","phase":"PHASE3","title":"Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract","status":"UNKNOWN","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2013-12","conditions":"Vesicoureteral Reflux, Renal Hypodysplasia, Nonsyndromic, 1, Chronic Kidney Disease","enrollment":292},{"nctId":"NCT05508152","phase":"PHASE3","title":"Prophylaxis of Surgical Wound Infection in Incisional Hernia Repair With Topical Antibiotics (PROTOP-PAR)","status":"COMPLETED","sponsor":"Hospital de Granollers","startDate":"2021-02-01","conditions":"Postoperative Hernia","enrollment":260},{"nctId":"NCT01581047","phase":"","title":"Pharmacokinetics of Small Spectrum Beta-lactam Antibiotics (Amoxicillin/Clavulanic Acid and Cefuroxime) in Patients on Intensive Care Units","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2012-03-15","conditions":"Infection","enrollment":37},{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":205},{"nctId":"NCT05224401","phase":"PHASE3","title":"Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs","status":"RECRUITING","sponsor":"Lund University","startDate":"2023-05-29","conditions":"Urinary Tract Infections, Bacteremia, Antibiotic Resistant Infection","enrollment":330},{"nctId":"NCT05051787","phase":"PHASE4","title":"Evaluation of Amoxicillin Diffusion in Breast Milk According to a Population Pharmacokinetic Approach (CONCEPTION-AMOX)","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2022-06-23","conditions":"Breast Feeding, Exclusive","enrollment":25},{"nctId":"NCT04751500","phase":"NA","title":"The HYsteroscopic Miscarriage MaNagement Trial: A Pilot RCT Investigating a Novel Management Pathway for RPOC","status":"COMPLETED","sponsor":"Birmingham Women's and Children's NHS Foundation Trust","startDate":"2021-01-31","conditions":"Retained Products After Miscarriage","enrollment":149},{"nctId":"NCT05664568","phase":"PHASE2","title":"The BLAST- 1 Trial - Cephalexin+Amoxicillin-clavulanate for Tuberculosis","status":"UNKNOWN","sponsor":"Western Sydney Local Health District","startDate":"2023-03-15","conditions":"Tuberculosis, Pulmonary","enrollment":30},{"nctId":"NCT03574090","phase":"PHASE4","title":"Study the Efficacy of Topical Antibiotherapy in the Prophylaxis of Incisional Surgical Infection in Colorectal Surgery","status":"COMPLETED","sponsor":"Universitat Internacional de Catalunya","startDate":"2020-10-20","conditions":"Surgical Wound Infection, Postoperative Wound Infection, Postoperative Wound Infection Superficial Incisional","enrollment":268},{"nctId":"NCT05896930","phase":"PHASE2","title":"Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"TASK Applied Science","startDate":"2017-11-09","conditions":"Pulmonary Tuberculosis","enrollment":134},{"nctId":"NCT04512638","phase":"PHASE4","title":"Best Treatment Choice for Osteonecrosis of the Jaw","status":"UNKNOWN","sponsor":"Tim Van den Wyngaert","startDate":"2021-01-01","conditions":"Medication Related Osteonecrosis of the Jaw","enrollment":125},{"nctId":"NCT04438655","phase":"NA","title":"Prospective Randomized Clinical Trial on Oral and Intravenous Antibiotic Prophylaxis in Colorectal Surgery.","status":"COMPLETED","sponsor":"University of Turin, Italy","startDate":"2019-05-01","conditions":"Colorectal Surgery","enrollment":130},{"nctId":"NCT05164887","phase":"","title":"Microbiota Implementation to Reduce Anastomotic Colorectal Leaks (MIRACLe)","status":"COMPLETED","sponsor":"S.Eugenio Hospital","startDate":"2020-12-01","conditions":"Colorectal Cancer, Surgery, LAP","enrollment":131},{"nctId":"NCT04476212","phase":"NA","title":"Prophylaxis of Surgical Wound Infection With Topical Antibiotics","status":"UNKNOWN","sponsor":"Hospital de Granollers","startDate":"2018-12-27","conditions":"Surgical Site Infection, Surgery--Complications, Colorectal Surgery","enrollment":560},{"nctId":"NCT04400110","phase":"PHASE4","title":"Short Therapy for Febrile UTI in Childhood","status":"COMPLETED","sponsor":"IRCCS Burlo Garofolo","startDate":"2020-06-08","conditions":"Urinary Tract Infections","enrollment":154},{"nctId":"NCT03755765","phase":"EARLY_PHASE1","title":"Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2019-07-23","conditions":"Antibiotic-associated Diarrhea","enrollment":66},{"nctId":"NCT03877289","phase":"PHASE4","title":"Efficacy of Oxybutynin in Paediatric Cystitis","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2008-10","conditions":"Cystitis","enrollment":81},{"nctId":"NCT05393505","phase":"PHASE4","title":"Fast-track Blood Test for Suspected Fever by Deficiency of a Kind of White Blood Cells As Main Defense Against Infection","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-10-24","conditions":"Neutropenic Fever","enrollment":344},{"nctId":"NCT04084106","phase":"PHASE4","title":"Effects of Phenoximethylpenicillin, Amoxicillin and Amoxicillin-clavulanic Acid on the Gut Microbiota","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2019-09-10","conditions":"Infectious Disease","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"administration":{"route":"Oral"},"crossReferences":{"chemblId":"CHEMBL2105950"},"_approvalHistory":[{"date":"20160823","type":"SUPPL","sponsor":"HIKMA PHARMS","applicationNumber":"ANDA203824"},{"date":"20230607","type":"SUPPL","sponsor":"HIKMA PHARMS","applicationNumber":"ANDA203824"},{"date":"20160823","type":"ORIG","sponsor":"HIKMA PHARMS","applicationNumber":"ANDA203824"},{"date":"20111220","type":"ORIG","sponsor":"AUROBINDO PHARMA LTD","applicationNumber":"ANDA201090"},{"date":"20240501","type":"SUPPL","sponsor":"AUROBINDO PHARMA LTD","applicationNumber":"ANDA201090"},{"date":"20240425","type":"SUPPL","sponsor":"AUROBINDO PHARMA LTD","applicationNumber":"ANDA201090"},{"date":"20260215","type":"SUPPL","sponsor":"AUROBINDO PHARMA LTD","applicationNumber":"ANDA201090"},{"date":"20240425","type":"SUPPL","sponsor":"AUROBINDO PHARMA LTD","applicationNumber":"ANDA201090"},{"date":"20150209","type":"SUPPL","sponsor":"AUROBINDO PHARMA LTD","applicationNumber":"ANDA201090"},{"date":"20240501","type":"SUPPL","sponsor":"AUROBINDO PHARMA LTD","applicationNumber":"ANDA201091"},{"date":"20111220","type":"ORIG","sponsor":"AUROBINDO PHARMA LTD","applicationNumber":"ANDA201091"},{"date":"20240411","type":"SUPPL","sponsor":"AUROBINDO PHARMA LTD","applicationNumber":"ANDA201091"},{"date":"20240411","type":"SUPPL","sponsor":"AUROBINDO PHARMA LTD","applicationNumber":"ANDA201091"},{"date":"20240411","type":"SUPPL","sponsor":"AUROBINDO PHARMA LTD","applicationNumber":"ANDA201091"},{"date":"19940418","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"19910522","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"20220825","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"20080327","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"20140930","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"20040811","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"19991119","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"20130122","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"20021017","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"19990201","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"20130122","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"19940706","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"20030512","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"19980211","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"19960216","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"20010417","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"19970319","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"19911105","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"19840806","type":"ORIG","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"19911205","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"20110929","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"20081204","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"20240501","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"20040603","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"19990923","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"19960304","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"20021204","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"20020410","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"19940915","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"19980211","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"19920721","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050575"},{"date":"20140922","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA065063"},{"date":"20060731","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA065063"},{"date":"20050602","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA065063"},{"date":"20020913","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA065063"},{"date":"20020821","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA065063"},{"date":"20240501","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA065063"},{"date":"20140922","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA065063"},{"date":"20060926","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA065063"},{"date":"20240429","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA065063"},{"date":"20220901","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA065063"},{"date":"20020821","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA065063"},{"date":"20020821","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA065063"},{"date":"20020314","type":"ORIG","sponsor":"SANDOZ","applicationNumber":"ANDA065063"},{"date":"20140922","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"ANDA065063"}],"publicationCount":98,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Amoxicillin and clavulanate","genericName":"Amoxicillin and clavulanate","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T05:05:26.826671+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}